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Abstract
The considerable variation in the spatial distribution of cortical thickness changes has been
used to parse heterogeneity in schizophrenia. We aimed to recover a ‘cortical
impoverishment’ subgroup with widespread cortical thinning. We applied hierarchical cluster
analysis to cortical thickness data of three datasets in different stages of psychosis and
studied the cognitive, functional, neurochemical, language and symptom profiles of the
observed subgroups. Our consensus-based clustering procedure consistently produced a
subgroup characterized by significantly lower cortical thickness. This ‘cortical
impoverishment’ subgroup was associated with a higher symptom burden in a clinically
stable sample and higher glutamate levels with language impairments in the first-episode
sample. Overall, cortical thinning is more prevalent among patients, especially those with
glutamate excess and speech dysfunctions in the early stages and higher residual symptom
burden at later stages.
Keywords
Hierarchical cluster analysis, Schizophrenia, Neurocognition, Cortical thickness, Magnetic
resonance spectroscopy, Heterogeneity, First-episode psychosis, Language impairment
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Summary for Lay Audience
Schizophrenia is one of the most disabling and chronic mental illnesses. Patients, despite
having the same diagnosis, can have very different clinical histories, symptom profiles and
treatment responses. This has posed challenges for clinicians to provide personalized
treatment plans. Therefore, researchers have made efforts to classify patients into subtypes,
so that this illness can be better understood and characterized. The current thesis pursued this
line of effort and aimed to find patient subtypes based on brain features. Compared to clinical
features that could be subjective and fluctuate over time, brain features are a more stable and
objective indicator of cognitive and mental health status. For example, cortical thickness, the
thickness of the outer layer of the brain, is found to be abnormal in some patients with
schizophrenia. It may be an important first step to differentiate patients with a healthy
cortical thickness profile from patients with lower cortical thickness, because these two
patient subgroups may represent distinct origins of the same illness.
Cluster analysis is a useful mathematical tool to identify patient subgroup(s) with different
brain profiles. It can assign patients with similar profiles to the same group, and then we can
determine when the subgroups are too distant to belong to one. In our study, we found that
there were two subgroups of patients in both chronic and first-episode schizophrenia. One
subgroup showed no difference in cortical thickness patterns from healthy controls, while the
other displayed cortical thinning in multiple regions of the brain. In chronic and stable
schizophrenia, patients with extensive cortical thinning experienced a higher residual
symptom burden. In first-episode schizophrenia, this subgroup showed an abnormal level of
glutamate. Glutamate is a molecule in our brain that sends signals to excite brain cells. This
subgroup also had impaired speech production such as simplicity in the structures of the
sentences, and reduced cohesion between sentences.
To conclude, a patient subgroup with widespread cortical thinning may represent a distinct
subtype which is stable across various stages of schizophrenia with dysregulated
neurochemical levels and abnormal language production. It may be important to customize
mental health care strategies for this subgroup of patients.

iii

Co-Authorship Statement
This thesis was adapted from two manuscripts, “Cortical impoverishment in a stable
subgroup of schizophrenia: Validation across various stages of psychosis”, published in May
2022 on Schizophrenia Research; and “Widespread Cortical Thinning, Excessive Glutamate
and Impaired Linguistic Functioning in Schizophrenia: A Cluster Analytic Approach”,
published in August 2022 on Frontiers in Human Neuroscience. Walter Heinrichs, Lena
Palaniyappan and Peter Francis Liddle supervised the individual study data collection and
analysis. Jean Theberge designed spectroscopy protocol and supervised Peter Jeon for MRS
data acquisition and analysis. Sabrina Danielle Ford and Michael MacKinley recruited
patients and collected clinical and speech data. Angelica M. Silva analyzed the speech data.
Liangbing Liang performed MRI data analysis and statistical analysis, designed the figures,
authored Chapters 1, 2 & 4, and co-authored Chapter 3 with Angelica M. Silva under the
supervision of Lena Palaniyappan.

iv

Acknowledgments
First and foremost, I would like to thank my supervisor Dr. Lena Palaniyappan, for offering
me valuable opportunities, ongoing mentorship, and tremendous encouragement throughout
my degree. Many thanks also go to my mentors and advisors, Drs. Walter Heinrichs, Marieke
Mur, Peter Liddle and Lyle Muller, who generously supported and believed in me, as well as
inspired and influenced me to develop my academic career.
I would like to extend my thanks to my colleagues in the NIMI group, especially Michael
MacKinley Angelica Silva, Peter Jeon, Sabrina Ford, Maria Fransisca Alonso Sanchez, and
Roberto Limongi. I am very grateful to have this research team to share my journey with.
Thank you for all the laughter and making me feel belonged, as well as being exceptionally
helpful when working on projects together. My sincere thanks also go to everyone who
assisted in clinical recruitment, data acquisition and patient care. I do not personally know
every one of them, but without the assistance of the participants, clinical staff, and research
team on the three individual projects, the outcome of the thesis would not be possible.
I would like to thank all funders who generously supported the research, especially a
studentship from Canada First Excellence Research Fund to BrainSCAN, Western
University. The individual studies received funding from the Canadian Institutes of Health
Research (CIHR) and Medical Research Council, respectively. The TOPSY study was
funded by CIHR Foundation Grant (grant number: 375104/2017) with data acquisition
supported by the Canada First Excellence Research Fund to BrainSCAN, Western University
(Imaging Core). NeuroCog study was supported by a CIHR operating grant (number:
102753), while CONN study was funded by Medical Research Council (G0601442).
I want to thank my partner Eric for giving me strengths and unconditional love during lows
and celebrated every single one of my achievements, no matter how small. I need to thank
my cat Elsa and my dogs Arya and Jack. My pets have given me accompany, loyalty and
pure love while working from home during pandemic and had been one of the reasons I felt
alive and motivated every day. Lastly, I am thankful for my parents and sisters, whom I love
dearly, for always being there for me when I need support.

v

Table of Contents
Abstract ............................................................................................................................... ii
Keywords ............................................................................................................................ ii
Summary for Lay Audience ............................................................................................... iii
Co-Authorship Statement................................................................................................... iv
Acknowledgments............................................................................................................... v
Table of Contents ............................................................................................................... vi
List of Tables ..................................................................................................................... ix
List of Figures ..................................................................................................................... x
List of Appendices ............................................................................................................ xii
Chapter 1 Introduction ........................................................................................................ 1
1.1.1

Symptoms of Schizophrenia ....................................................................... 1

1.1.2

Treatment, Outcome and Course of Schizophrenia .................................... 1

1.1.3

Schizophrenia as a Thought Disorder ......................................................... 2

1.1.4

Schizophrenia as a Brain Disorder .............................................................. 3

1.1.5

Heterogeneity of Schizophrenia .................................................................. 4

1.1.6

Parsing Heterogeneity of Schizophrenia ..................................................... 5

1.1.7

Project Overview ........................................................................................ 6

Chapter 2 Cortical Impoverishment Subgroup in Chronic Schizophrenia ......................... 7
2.1 Background ............................................................................................................. 7
2.1.1

Dissecting Heterogeneity in schizophrenia ................................................. 7

2.1.2

Thickness-based Clustering ........................................................................ 8

2.1.3

Aims of Study ............................................................................................. 9

2.2 Material and Methods ........................................................................................... 10
2.2.1

Participants ................................................................................................ 10

2.2.2

Measures ................................................................................................... 11
vi

2.2.3

MRI and MRS Data Acquisition and Processing ..................................... 11

2.2.4

Statistical Analysis .................................................................................... 12

2.3 Results ................................................................................................................... 14
2.3.1

Demographic and Clinical Characteristics of Participants ....................... 14

2.3.2

Clustering Solution and Composition ....................................................... 16

2.3.3

Neuroanatomical Differences Between Clusters ...................................... 19

2.3.4

Characteristics of Participants in Each Cluster ......................................... 22

2.3.5

Cognitive Characteristics .......................................................................... 22

2.3.6

Clinical Characteristics ............................................................................. 24

2.3.7

Exploratory Analysis of Symptoms, Cognition and Medication .............. 25

2.4 Discussion ............................................................................................................. 28
2.4.1

Discovery and Validation of Two thickness-based subgroups ................. 28

2.4.2

Aggregation of patients and controls ........................................................ 29

2.4.3

Similarities between the two thickness-based subgroups ......................... 29

2.4.4

Differences between the two thickness-based subgroups ......................... 31

2.4.5

Limitations ................................................................................................ 32

Chapter 3 Cortical Impoverishment Subgroup in First-episode Psychosis....................... 33
3.1 Introduction ........................................................................................................... 33
3.1.1

Language Deficits in Schizophrenia ......................................................... 33

3.1.2

Computational Measures of Language Deficits ........................................ 34

3.1.3

Detecting Subgroups with Language Dysfunctions .................................. 35

3.1.4

Cortical thickness-based Subgroups ......................................................... 36

3.1.5

Cortical thickness and Glutamate ............................................................. 36

3.1.6

Negative FTD-related Language Features ................................................ 37

3.1.7

Hypotheses ................................................................................................ 37

3.2 Methods................................................................................................................. 38
vii

3.2.1

Participants ................................................................................................ 38

3.2.2

Measures and instruments ......................................................................... 39

3.2.3

Psychiatric Symptoms............................................................................... 39

3.2.4

Thought and Language Index (TLI) ......................................................... 39

3.2.5

Language assessment ................................................................................ 40

3.2.6

MRI and MRS Acquisition and Processing .............................................. 41

3.2.7

Statistical Analyses ................................................................................... 41

3.2.8

Sensitivity Analyses .................................................................................. 42

3.3 Results ................................................................................................................... 43
3.3.1

Subgroup Characteristics .......................................................................... 43

3.3.2

Cluster Solution Consistency .................................................................... 52

3.4 Discussion ............................................................................................................. 54
3.4.1

‘Cortical Impoverishment’ Subgroup ....................................................... 54

3.4.2

Cortical Thinning and Glutamate Excess ................................................. 54

3.4.3

Cortical Thinning and Language Deficits ................................................. 55

3.4.4

Syntactic Simplicity in ‘Cortical Impoverishment’ Subgroup.................. 55

3.4.5

Impaired Cohesion in ‘Cortical Impoverishment’ Subgroup.................... 56

3.4.6

Strengths ................................................................................................... 57

3.4.7

Limitations ................................................................................................ 57

Chapter 4 Conclusions ...................................................................................................... 59
4.1 Future Directions .................................................................................................. 59
Appendices ........................................................................................................................ 62
References ......................................................................................................................... 74
Curriculum Vitae ............................................................................................................ 117

viii

List of Tables
Table 1 Demographic, cognitive and clinical information of ‘Discovery’ and ‘Validation’
dataset. .................................................................................................................................... 14
Table 2 Medication information of patients in the NeuroCog study ...................................... 15
Table 3 ‘Cortical impoverishment’ subgroup membership when clustering is carried out with
or without the data from healthy controls. .............................................................................. 18
Table 4 Top 5 cortical parcellations that showed largest effect sizes in thickness between
patients of the two clusters. ..................................................................................................... 21
Table 5 Demographic, clinical, neurobiological, and linguistic data of patients with firstepisode psychosis and healthy controls .................................................................................. 45
Table 6 Demographic, clinical, neurobiological, and linguistic data of subgroups. ............... 46
Table 7 Cortical regions with their area size (mm2) showed significant differences after
Monte Carlo simulation correction between patients from the two subgroups, in the left and
right hemispheres respectively. ............................................................................................... 51
Table 8. Sensitivity analyses to examine the effects of different methods on findings. ......... 52

ix

List of Figures
Figure 1 Hierarchical cluster dendrogram of the ‘Discovery’ and ‘Validation’ samples ....... 17
Figure 2 Bar plots of the frequency of proposed cluster solutions, when clustering with
patients and healthy controls. .................................................................................................. 17
Figure 3 Bar plots of the frequency of proposed cluster solutions, when clustering with
patients only. ........................................................................................................................... 18
Figure 4 Distribution of patients and healthy controls in the two thickness-based clusters in
the two studies......................................................................................................................... 19
Figure 5 Cortical thickness maps of differences between members of the two clusters in the
discovery dataset. .................................................................................................................... 21
Figure 6 Comparisons of cognitive characteristics of members in each cluster in the
NeuroCog 'Discovery' Sample. ............................................................................................... 23
Figure 7 Comparisons of clinical characteristics of patients in each cluster. ......................... 25
Figure 8 Relationships between cognitive test scores, symptoms severity measurements and
antipsychotics defined daily dose in Cluster 1 and Cluster 2 patients, respectively in the
NeuroCog ‘Discovery’ Sample. .............................................................................................. 27
Figure 9 Raincloud plots depicting the comparisons of distributions between the two patient
subgroups. ............................................................................................................................... 49
Figure 10 Cortical thickness map of differences between patients from Subgroup 1 and
Subgroup 2 generated by FreeSurfer (regressing out age effect with a general linear model,
uncorrected). Left hemisphere and right hemisphere in lateral and medial view respectively.
................................................................................................................................................. 50
Figure 11 Cortical thickness map of differences between patients from Subgroup 1 and
Subgroup 2 generated by FreeSurfer. ..................................................................................... 50

x

Figure 12 Cortical regions that are correlated with dACC glutamate levels (uncorrected)
generated by FreeSurfer. ......................................................................................................... 52

xi

List of Appendices
Appendix A. Language Metrics .............................................................................................. 62
Appendix B. Patient Speech Data Examples .......................................................................... 63
Appendix C. Tissue volume fractions in the voxel placed in dorsal anterior cingulate cortex.
................................................................................................................................................. 64
Appendix D. Description of single voxel 1H-MRS of MRS hardware, data acquisition,
analysis, and quality assessment details.................................................................................. 64
Appendix E. Two different cortical parcellation maps ........................................................... 66
Appendix F. Bash Scripts and R Codes .................................................................................. 67
Appendix G. Journal Copyright Policies ................................................................................ 72

xii

1

Chapter 1

Introduction

Chapter 1 Introduction provides an overview of symptoms, course, outcome, treatment,
etiology, and neurobiological basis of schizophrenia. This chapter will discuss and
emphasize schizophrenia as a thought disorder (with language dysfunctions) as well as a
brain disorder (neuroanatomical and neurochemical abnormality), with a focus on datadriven approaches to investigate its heterogeneous nature.

1.1

Symptoms of Schizophrenia

Schizophrenia is a severe and chronic mental illness that affects the patients’ perception,
cognition, emotion, language production and thought processes (Ross et al., 2006).
According to the most recent edition, the 5th edition of the Diagnostic and Statistical
Manual of Mental Disorders (DSM-5), key symptomatic characteristics of schizophrenia
include delusions, hallucinations, disorganized speech/behaviours, and negative
symptoms (Tandon et al., 2013b). Psychotic symptoms such as hallucination (sensations
without external stimuli), and delusion (false and rigid beliefs), are also described as
positive symptoms, whereas negative symptoms describe the absence of healthy emotions
and behaviours, such as lack of emotional expression, social withdrawal, inattention to
environmental inputs, and poverty of speech (American Psychiatric Association, 2013).
Furthermore, there is a third group of symptoms, termed cognitive symptoms. Compared
to healthy populations, patients diagnosed with schizophrenia have impaired cognitive
abilities in multiple domains including working memory, processing speed, social
cognition, attention/vigilance and executive functioning (Ross et al., 2006).

1.2

Treatment, Outcome and Course of Schizophrenia

Schizophrenia affects around 1% of the population (McGrath et al., 2008) and typically
develops around late adolescence and early adulthood (Kirkbride et al., 2012). Before
illness onset, patients in the prodromal phase may start to perform poorly in academic,
employment or social settings (Møller & Husby, 2000) as well as experiencing brief
psychotic-like symptoms (Fusar-Poli, Borgwardt, et al., 2013). Psychotic symptoms are
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often episodic and can be effectively alleviated by antipsychotic medications in around
70% of patients (Elkis, 2007), but the response to treatment varies greatly (Case et al.,
2011). In contrast, negative symptoms and cognitive impairments tend to persist in
chronic schizophrenia despite medications (Jauhar et al., 2022). Due to the presence of
psychotic, negative and cognitive symptoms, patients often have difficulties in
occupational functioning, personal relationships or self-care (Bowie & Harvey, 2006;
Tandon et al., 2013b) and only around 15%-40% of patients have good functional
outcome according to a few meta-analyses (Jauhar et al., 2022). Early intervention has
been found to be beneficial for both clinical and functional recovery (Correll et al., 2018).

1.3

Schizophrenia as a Thought Disorder

Formal Thought Disorder (FTD) describes impairments in organizing thoughts logically
and purposefully, and expresses frequently in schizophrenia (Ayer et al., 2016; Jerónimo
et al., 2018). In general, FTD is commonly characterized by impoverishment (e.g., slow
thinking) and disorganization (e.g., thought interference) of thoughts. FTD can manifest
itself as overt communication difficulties and language dysfunctions (Kircher et al.,
2018b; Liddle, Ngan, Caissie, et al., 2002a). Impoverishment of speech describes reduced
quantity in speech contents, conceptualized as negative FTD; while disorganization of
speech is characterized by incoherence and looseness of language use, conceptualized as
positive FTD (Kircher et al., 2018b; Palaniyappan, 2021a). The most affected domains of
linguistic functioning included semantic, syntactic and pragmatic levels of language use
(Covington et al., 2005; Kircher et al., 2018b).
Thought disorder and speech production impairment can be measured clinically or
computationally. Clinical rating scales such as the Thought and Language Disorder scale
(Kircher et al., 2014) or the Thought and Language Index (Liddle, Ngan, Caissie, et al.,
2002a) capture a variety of FTD symptoms. Additionally, thought and speech production
deficits can be objectively quantified using novel computational approaches combined
with linguistic analyses. For example, natural language processing (NLP) uses computer
algorithms to extract linguistic features (e.g. syntactic complexity, word type usage), and
has been found to capture subtle language disturbances in schizophrenia (Tang et al.,
2021). Specifically, patients with schizophrenia tend to have lower similarity within
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neighbouring sentences, reduced semantic density, shorter sentence length and lack of
referential word use (Corcoran et al., 2020).

1.4

Schizophrenia as a Brain Disorder

The etiology of the illness is not yet known, but it is widely agreed that a wide range of
genetic and environmental factors lead to changes in neurochemistry, structure or
functions of the brain, which lead to the onset of psychotic symptoms (Tsuang, 2000).
According to large-scale genome-wide association studies (GWAS), schizophrenia is
heritable, with hundreds of common genetic variants that increase the risk for psychosis
by a very small proportion, and a few rare genetic variants that have large effect sizes
(Smeland et al., 2020). As for environmental vulnerability factors, it has been reported
that birth complications, immigration, exposure to viruses during the prenatal period, and
stressful life events can increase the risk for schizophrenia (Tsuang, 2000). The genetic
and environmental risk factors leading to the condition vary across patients and this has
complicated etiologic research that aims to pinpoint risk factors and the neurobiological
causes of the illness.
As various brain imaging tools and analytic methods become readily available, we are
now able to measure the molecules, structures, functions, and physiology of the brain, a
large amount of evidence shows that schizophrenia is associated with abnormality in the
brain (Ross et al., 2006) and is a biologically based brain disease. One of the brain
imaging tools used constructs 3-dimensional images of the brain to uncover the brain
structures including grey matter, white matter, ventricles, and subcortex. For example,
computerized tomography (CT) and magnetic resonance imaging (MRI) can both inform
us of neuroanatomical features, including gyrification, cortical thickness and brain
volumes. Another brain imaging tool is magnetic resonance spectroscopy (MRS) which
can be used to determine the concentrations of biochemicals in a certain location of the
brain.
Although many studies have shown a difference in neurobiology between healthy
controls and patients diagnosed with schizophrenia, a common biomarker that lies in the
pathway to schizophrenia has not yet been identified. The lack of clear neuropathogenesis
of schizophrenia after years of research has prompted many researchers to look for
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multiple pathophysiological pathways. There have been multiple hypotheses on the
neurobiological pathogenic pathways to schizophrenia (Smeland et al., 2020). The most
influential theories postulate that the dysregulation of neurotransmitters including
dopamine, glutamate and/or GABA in the striatum, hippocampus, prefrontal cortex, and
midbrain leads to psychosis. Another model describes psychosis as a neurodevelopmental
disorder (Smeland et al., 2020). The neurodevelopmental model of psychosis theorizes
that abnormal development of the brain, specifically structure, connectivity and
physiology, results in aberrant information processing (Smeland et al., 2020). In general,
patients with schizophrenia, compared to healthy controls, have initial and progressive
loss of grey and white matter volume and an increase in ventricular volume (Fusar-Poli,
Smieskova, et al., 2013; Haijma et al., 2013; Olabi et al., 2011; Vita et al., 2012). Patients
also have widespread cortical thickness reduction that progresses more quickly with age,
illness duration and higher antipsychotic medication exposure (van Erp et al., 2018).

1.5

Heterogeneity of Schizophrenia

The various pathogenic models of schizophrenia further support the polygenetic and
multifactorial architecture of schizophrenia. These models are not mutually exclusive, but
instead, they can co-manifest to different degrees in patients. This suggests that patients
could have divergent abnormalities in multiple neural systems at varied impaired levels
that contributed to different subtypes of schizophrenia or converged to a dimension that
cut across the schizophrenia spectrum (Ruan et al., 2020). The wide range and variations
of brain abnormalities that we observed in schizophrenia are discussed as neurobiological
heterogeneity. Neurobiological heterogeneity in schizophrenia can be demonstrated by
the great variations of measurements obtained from patients, and the lack of high effectsize differences in patients as a single group, compared to the unaffected, apparently
healthy population.
It is not surprising to expect heterogeneity in the underlying biological mechanisms of
schizophrenia, because the diagnosis of schizophrenia itself is solely based on symptoms
without assisting biological tests, and has naturally brought in a level of clinical
heterogeneity based on the diagnostic criteria. Based on the DSM-5 (American
Psychiatric Association, 2013), out of the five major symptom categories (e.g.
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hallucinations, delusions, disorganized speaking, disorganized movements and negative
symptoms), the presence of two symptoms meets the diagnostic criteria, alongside social
or occupational dysfunctions. In other words, two patients with the same diagnosis can
share no symptoms in common.
Heterogeneity of schizophrenia can become problematic when we try to discover
biologically guided treatment options in relation to disease mechanisms, because great
variances can produce inconsistent results with small effect sizes which masks us from
identifying meaningful biomarkers that can be used for diagnosis, prognosis, and
outcome prediction (Marquand et al., 2016).

1.6

Parsing Heterogeneity of Schizophrenia

Research into the diagnosis, prognosis and treatment of schizophrenia could be better
informed if the heterogeneity of schizophrenia can be parsed to identify meaningful
subgroups of patients. One way to achieve this is by applying typologies to organize
patients with unsupervised machine learning approaches (Jablensky, 2010). Such
subtyping strategies have been summarized in a systematic review (Habtewold et al.,
2020), based on symptoms and cognitive performance. The data analyzed were generally
collected from patient self-reports, clinical interviews or observations of symptoms, or
scores from psychiatric rating scales or neuropsychological tests, but this approach has
three major problems: (I) patients’ symptoms are rated via subjective clinical judgments;
these are prone to multiple sources of measurement bias (Everitt et al., 1971; Tandon et
al., 2013a); (II) the assumption that patients with similar clinical or cognitive profiles
share common underlying pathophysiological mechanisms is an untested one. In other
words, symptoms- or cognitive ability-based patient subtypes may not be biologically
homogeneous; this will continue to impede our ability to develop mechanistically
informed diagnosis, treatment and prediction; (III) Symptom severity and cognitive
performance measurements are time-varying parameters; they change throughout the
course of the illness (Dollfus & Petit, 1995; Miles et al., 2014), which may lead to
temporal instability in symptom- or cognition-based subtypes. Stable and accurate
classification systems are important because they would help explain disease mechanisms
and inform clinical decisions, especially the development of tailored treatment.
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1.7

Project Overview

Data-driven subtypes of schizophrenia have focused primarily on symptoms and
cognitive performance (Habtewold et al., 2020; Schnack, 2019) and Clementz et al. were
one of the research groups to investigate biotypes in schizophrenia (Clementz et al., 2016,
2020, 2021), and also multiple other studies make efforts in discovering neuroanatomical
or physiological subtypes of schizophrenia (Dwyer et al., 2018a; Honnorat et al., 2019a;
Pan et al., 2020a; Sugihara et al., 2017a). Brain-based patient subtyping may facilitate the
transition from subjective clinical judgment to objective biology-grounded clinical
practice, which aligns with the goals of The National Institute of Mental Health's
Research Domain Criteria (RDoC) (Insel et al., 2010). This study continued the efforts of
brain-based patient subtyping and was conducted with three schizophrenia patient
samples of different clinical statuses, which were independently recruited across different
geographical locations, and scanned with different MRI scanners.
Our primary aim was to confirm the existence of a cortical impoverishment subgroup of
schizophrenia by capturing the variation in cortical thickness across patients and healthy
controls matched for IQ. Second, we aimed to test the validity of cortical thickness-based
subtypes across various clinical stages, antipsychotic exposure rates, and functional
stability in 2 other samples with patients at different stages of schizophrenia. We
predicted that a constant ‘cortical impoverishment’ subgroup would emerge irrespective
of early vs. late stages of schizophrenia, acute vs. chronic symptom status, and minimal
vs. chronic exposure to antipsychotics. Third, we leveraged the multimodal ultra-high
field MRS and MRI data available from one of the 3 samples to investigate if patients
with pronounced cortical impoverishment also showed glutamatergic excess. Given that
the spectral resolution for precise quantification of glutamate in vivo is currently only
feasible at ultra-high field strengths, this method provides robust evidence linking
glutamatergic excess to cortical impoverishment in schizophrenia.
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Chapter 2

Cortical Impoverishment Subgroup in Chronic
Schizophrenia

Cortical thinning is a well-known feature in schizophrenia. The considerable variation in
the spatial distribution of thickness changes has been used to parse heterogeneity. A
‘cortical impoverishment’ subgroup with a generalized reduction in thickness has been
reported. However, it is unclear if this subgroup is recoverable in chronic schizophrenia.
Chapter 2 aimed to replicate the cortical thinning subgroup in chronic schizophrenia and
validate the finding in a second chronic sample. We found that cortical thinning does not
vary with functioning or cognitive impairment, but it is more prevalent among patients,
especially those with higher residual symptom burden at stable stages. This chapter was
adapted from the manuscript published on Schizophrenia Research 1.

2.1

Background

2.1.1 Dissecting Heterogeneity in schizophrenia
Schizophrenia spectrum disorders are characterized by individual differences in clinical
trajectory, symptom burden, and cognitive performance (Andreasen, 1999; Carpenter &
Kirkpatrick, 1988). The source of this heterogeneity is unknown, but suspected to arise
from etiological and neurobiological variations (Lv et al., 2020; Alnæs et al., 2019;
Brugger & Howes, 2017), possibly reflecting multiple neuropathological pathways to the
disorder (Seaton et al., 2001). To dissect this heterogeneity, several attempts have been
made using cluster analysis, a multivariate technique to discover subgroups with minimal
within-group variance for a variable of interest (Everitt et al., 2011). Cluster analytic
strategies have been applied to cognitive (Cobia et al., 2011; Geisler et al., 2015;
Heinrichs & Awad, 1993; Van Rheenen et al., 2017; Weinberg et al., 2016), clinical
(Dickinson et al., 2018; Dollfus & Brazo, 1997; Talpalaru et al., 2019), physiological
(Clementz et al., 2015), and neurobiological (Chand et al., 2020b; Dwyer et al., 2018b;

1

A version of this chapter has been published on Schizophrenia Research (Liang, Heinrichs, et al., 2022).

8

Honnorat et al., 2019b; Pan et al., 2020b; Planchuelo-Gómez et al., 2020; Sugihara et al.,
2017b) variables to delineate subtypes in schizophrenia. Subgrouping patients based on
neuroanatomy has a particular appeal. First, it is advantageous to look directly at the
underlying neurobiological substrate of psychosis instead of the downstream emergent
clinical features (e.g., symptoms or functioning), as highly similar clinical profiles can
emerge from varying mechanistic processes. Second, neuroanatomical data are relatively
stable metrics that are accessible from 7-10 minutes of non-invasive structural magnetic
resonance imaging (MRI) scanning. Finally, in contrast to the use of symptom measures
for clustering, neuroanatomical data allow us to pool both patients and healthy controls
into one sample for analysis. Although differences in multiple neurobiological variables
between patients with schizophrenia and healthy controls have been reported (Gong et al.,
2020; van Erp et al., 2018), treating patients and controls as completely distinct groups in
case-control neuroimaging studies ignores the shared variance (Voineskos et al., 2020)
and also assumes that there is no useful subgrouping information within the healthy
samples. Deriving neurobiological subgroups without considering diagnostic statuses
allows us to leverage ‘healthy variations’ in addition to pathological inter-individual
differences and investigate how patients and controls naturally aggregate and separate in
the biological feature space.

2.1.2 Thickness-based Clustering
Cortical thickness is useful as a variable to aggregate patients in subgroups alongside
healthy controls. Several studies have documented deviations in cortical thickness
patterns in patients in relation to symptom severity, but the spatial distribution of
thickness changes is heterogeneous with effect sizes being small to moderate (Kuperberg
et al., 2003; Narr et al., 2005; Schultz et al., 2010; van Erp et al., 2018; van Haren et al.,
2011; Goldman et al., 2009), indicating the possible existence of subgroups with varying
locations and degree of thickness change. Furthermore, region-specific cortical deficits
associate with more severe positive and negative symptoms (Walton et al., 2018; Xiao et
al., 2015), cognitive dysfunction (Hartberg et al., 2011), and treatment resistance
(Zugman et al., 2013). While the mechanistic pathways influencing the diffuse reduction
in cortical thickness are yet unclear, some studies that combine structural imaging and
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magnetic resonance spectroscopy (MRS) suggest glutamate-mediated excitotoxicity as
one of the mechanisms underlying thickness changes in schizophrenia (Plitman et al.,
2016; Shah et al., 2020). These findings highlight the utility of profiling patients based on
cortical thickness when attempting to uncover mechanistically homogeneous subgroups
of schizophrenia.
A distinct subgroup has emerged in previous cortical thickness-based clustering of
schizophrenia patients and healthy subjects (Pan et al., 2020b; Sugihara et al., 2017b).
This subgroup predominantly comprised patients with significantly reduced cortical
thickness compared to other subgroups. It parallels with clustering based on cognitive
measures (especially IQ) across diagnostic boundaries (Van Rheenen et al., 2017), which
has also identified a broadly compromised subgroup. Studies have linked cortical
thickness to IQ in both healthy subjects (Deary et al., 2010) and patients with
schizophrenia (Cobia et al., 2011). In prior thickness-based clustering studies (Pan et al.,
2020b; Sugihara et al., 2017b), patients had notable cognitive deficits compared to
healthy subjects; as a result, it is unclear if the patient-dominant ‘cortical
impoverishment’ subgroup occurs independently of cognitive heterogeneity among the
individuals under consideration. A recent study (Xiao et al., 2021) reported a subgroup of
established cases of schizophrenia to have cortical impoverishment and higher cognitive
deficits. However, this study clustered only patients, without leveraging the variability
among healthy subjects. Taken together, the evidence does not clearly indicate whether
cortical impoverishment subgroups are simply patients with general intellectual
impairment (Carruthers et al., 2019). Furthermore, we do not know whether the presence
of the cortical impoverishment subgroup is related to ageing effects (Y. Lin et al., 2019)
or could be the result of exposure to higher doses of antipsychotic medications rather than
a distinct disease process in a subset of patients (Fusar-Poli, Smieskova, et al., 2013; Ho
et al., 2011).

2.1.3 Aims of Study
Our primary aim was to confirm the existence of a cortical impoverishment subgroup of
schizophrenia by capturing the variation in cortical thickness across patients and healthy
controls matched for cognitive ability. To this end, we recruited 136 subjects; 73 with

10

established schizophrenia and 63 with age, sex, years of education, and IQ-matched
healthy controls. Second, we aimed to test the validity of cortical thickness-based
subtypes across various clinical stages, and functional stability. We predicted that a
constant ‘cortical impoverishment’ subgroup would emerge irrespective of illness
duration and illness stability. To this end, we validated the stability of our clustering
solution in the IQ-matched ‘discovery’ dataset in another sample with patients (n=41).

2.2

Material and Methods

2.2.1 Participants
Data used in the present study were obtained from two previously reported patient
samples, with each sample in different clinical stages, antipsychotic exposure rates, and
functional stability. Written informed consent was obtained from all participants.
The primary dataset for the ‘discovery’ approach (NeuroCog Dataset) was composed of
63 healthy controls and 73 patients with a DSM-IV diagnosis (First et al., 1996) of
schizophrenia or schizoaffective disorder recruited through outpatient programs in
Hamilton, Ontario, Canada. Most of the patients were taking antipsychotics and had
chronic schizophrenia. To enable cognitively matching patients and controls, controls
were oversampled from communities with lower employment and education levels, while
patients with near-normal cognition were specifically sought, eventually capturing both
cognitively normal patients and sub-normal healthy controls. Details on participant
recruitment have been previously reported (Heinrichs et al., 2017; Hanford et al., 2019).
This study was approved by York University (#2010-107), St. Joseph's Healthcare,
Hamilton, and McMaster University (#10-3315) review boards.
The validation dataset (CONN Dataset) was composed of 40 healthy controls (groupmatched for sex, age and parental socioeconomic status measured using National
Statistics Socio-Economic Classification (NS-SEC; Rose et al., 2005), to reduce
confounding due to psychosocial differences during early development) and 41 patients
with a DSM-IV diagnosis (First et al., 1996) of schizophrenia or schizoaffective disorder,
recruited through community-based services in Nottinghamshire, United Kingdom.
Unlike the ‘discovery’ sample, CONN patients were recruited only if they satisfied
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‘stable illness phase’ criteria, which were that patients needed to have no change in
medication over the prior 6 weeks and no more than 10 points change in their Global
Assessment of Function [DSM-IV] score, assessed 6 weeks prior and immediately before
study participation. Recruitment of participants and data collection has been described
previously (Palaniyappan & Liddle, 2014) and was approved by National Research Ethics
Committee, Nottinghamshire (NHS REC Ref: 10/H0406/49).

2.2.2 Measures
In the NeuroCog project, the MATRICS (Measurement and Treatment Research to
Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB) was
administered to all participants to measure abilities in seven different cognitive domains,
including working memory, attention or vigilance, verbal memory and learning,
processing speed, problem-solving, visual learning, and social cognition (Kern et al.,
2008; Nuechterlein et al., 2008). IQ scores of all participants were measured with the
Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler, 1999). The patients’
symptom severity was assessed with the 30-item Positive and Negative Syndrome Scale
(PANSS-30) to index positive, negative, and general psychopathology (Kay et al., 1987).
The Canadian Objective Assessment of Life Skills (COALS) was administered to index
functional competence (McDermid Vaz et al., 2013).
The validation sample was acquired in the CONN studies. In the CONN study, we used
the Signs and Symptoms of Psychotic Illness (SSPI) (Liddle, Ngan, Duffield, et al., 2002)
to measure symptom severity and the Social and Occupational Functional Assessment
Scale (SOFAS) to measure the overall functioning (Morosini et al., 2000a) of patients.
This sample did not have a detailed cognitive characterization that was available for the
discovery dataset.

2.2.3 MRI and MRS Data Acquisition and Processing
The details of data acquisition in the NeuroCog and CONN projects (3.0-Tesla MRI)
have been reported previously (Heinrichs et al., 2017; Palaniyappan & Liddle, 2014) and
are summarized here. In the NeuroCog ‘Discovery’ Dataset, a 3.0-Tesla whole-body

12

short bore General Electric System MRI scanner equipped with an 8-channel parallel
receiver head coil was used to scan participants at the Imaging Research Centre at St.
Joseph’s Healthcare Hamilton. Anatomical images of 152 slices (2 mm thick with 1 mm
overlap) were generated. The scanning parameters of T1-weighted 3-dimensional fast
spoiled gradient recalled echo sequence with inversion recovery preparation were as
follows: repetition time (TR)/echo time (TE) = 7.5/2.1 ms, TI = 450 ms, field of view
(FOV) = 24 cm, matrix = 512 × 512, flip angle = 12°, receiver bandwidth (rBW) =
+/−62.5 kHz, and number of excitations (NEX) = 1. In the CONN ‘Validation’ Dataset,
MR scans were collected with Philips 3.0-Tesla imaging systems which were equipped
with an 8-channel phased array head coil in the University of Nottingham. The scanning
protocol included a single high-resolution three-dimensional T1-weighted MPRAGE
volume of isotropic voxel size 1 × 1 × 1 mm3, TR/TE = 8.1/3.7 ms, flip angle 8°, field of
view 256 × 256 × 160 mm3, 160 slices of 1 mm thickness each were collected in an
acquisition matrix 256 mm × 256 mm and in-plane resolution 1 × 1 mm2.
The obtained images underwent FreeSurfer automated image analysis for alignment of
cortical regions and segmentation of the brain (version 5.1.0;
http://surfer.nmr.mgh.harvard.edu/) (Fischl et al., 1999). Preprocessing of these images
included the removal of non-brain tissues as well as spatial and intensity normalizations.
Cortical thickness was defined as the Euclidean distance between the pial surface to the
grey/white matter boundary across 160,000 vertices in both cerebral hemispheres.
Cortical regions were assorted according to the gyral and sulcal structures in both
hemispheres defined by Destrieux et al. (2010).

2.2.4 Statistical Analysis
This study applied agglomerative hierarchical cluster analysis to age-corrected cortical
thickness values among 148 brain regions with the hclust function in R (R Core Team,
2020). Thickness values of 148 cortical regions of interest were adjusted for age with
linear regression, and the residuals were input as variables for clustering. Ward’s method
with Euclidean distance was used. We visually inspected the dendrogram to determine
the possible stratification solutions.
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The NbClust function in R statistical software was used to determine the optimal number
of clusters. The NbClust function in R packages (Charrad et al., 2014) offers multiple
clustering validity indices and outputs the recommended number of clusters for each
validity index. In the current study, 16 validity indices in the NbClust package were
selected to evaluate the clustering results ("ch", "cindex", "kl", "hartigan", "db",
"silhouette", "ratkowsky", "ball", "ptbiserial", "gap", "mcclain", "gamma", "gplus", "tau",
"dunn", "sdindex"). These validity indices either regard the elbow point as optimal, or
attempt to reach the maximum ratio of inter-cluster separation over intra-cluster
compactness. The optimal number of clusters was determined by the consensus of the 16
validity indices.
To assess external validity, key characteristics of each cluster were compared across
clusters, including illness prevalence, antipsychotic exposure, cortical thinning patterns,
socio-demographic, clinical, and cognitive information as well as neurometabolic levels.
Clinical information included duration of illness (years) and symptom severity measured
by PANSS or SSPI. MCCB composite scores were converted into T scores (mean = 50,
SD = 10). Antipsychotic medication dose equivalents were calculated based on Defined
Daily Doses (DDDs) according to the World Health Organization (WHO) guidelines
(http://www.whocc.no). Multiple Student or bootstrapped t-tests (two-tailed, α<0.05)
were used for comparison of continuous variables, while chi-square tests (two-tailed,
α<0.05) were used for comparisons of non-categorical variables between participants in
each cluster.
In the ‘discovery’ dataset, Pearson correlation coefficients between medication exposure,
symptom severity, and cognitive performance were calculated tested for significance for
patients in each subgroup, respectively. The correlation magnitudes retrieved from the
two subgroups of patients were tested against each other with a two-tailed z-test using
Fisher’s z transformation of correlations.
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2.3

Results

2.3.1 Demographic and Clinical Characteristics of Participants
Demographic and clinical details were summarized in Table 1. The patient sample in
NeuroCog (average illness duration = ~17 years) and CONN (average illness duration =
~7 years) consisted of patients with chronic schizophrenia or schizoaffective disorder,
with 85% of the NeuroCog sample and 88% of the CONN sample taking antipsychotic
medications at the time of scanning (Table 2).
Table 1 Demographic, cognitive and clinical information of ‘Discovery’ and
‘Validation’ dataset.

N
Age
Demographics

Cognitive
Measurements

Female/ma
le
Education,
years
MCCB
total T
score
WASI

Functional
Outcome
MRI data

Symptom
Severity

COALS
SOFAS

NeuroCog Study
‘Discovery’ Dataset
Patients
Controls
73
63
41.42 ±
38.87 ±
10.48
11.46

CONN Study
‘Validation’ Dataset
Patients
Controls
41
40
33.63 ±
33.40 ± 9.10
9.24

29/44

24/39

10/31

11/29

12.90 ±
2.20

12.48 ± 2.24

-

-

29.26 ±
13.13

41.38 ±
14.31

-

-

96.42 ±
21.16
35.66 ±
10.83

101.19 ±
20.38

-

-

-

-

-

-

-

54.63 ±
13.11

-

2.43 ± 0.38

2.44 ± 0.38

Global CT,
2.45 ± 0.37 2.53 ± 0.37
mm
Patients Only
PANSS or
SSPI
PANSS-30:
(Median
61[51, 70]
[IQR])
Min-max
normalized 0.20 ± 0.087
score

Patients Only
SSPI:
11[5, 18]

0.15 ± 0.093
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Clinical
Information

Antipsychotic
Medication

Duration
of Illness
(Median
[IQR])

17 [9.75, 25], in years

Median
DDD

Mea
n

IQR

6 [4, 14], in years

Median

Mea
n

IQR

[0.73,
[0.42,
1.25
2.03
1.66]
2.84]
Note: Means and standard deviations are reported unless specified otherwise. IQR:
1.00

1.30

interquartile range is the first and third quartile. T scores are standardized scores with a
mean of 50 and standard deviation of 10. MCCB: MATRICS (Measurement and
Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive
Battery; WASI: Wechsler Abbreviated Scale of Intelligence; COALS: Canadian
Objective Assessment of Life Skills; SOFAS: Social and Occupational Functioning
Assessment Scale; Global CT: average cortical thickness across the whole brain
(measured in millimetres); PANSS: Positive and Negative Syndrome Scale; SSPI: Signs
and Symptoms of Psychotic Illness; DDD: defined daily dose calculated according to
World Health Organization (http://www.whocc.no). Symptom severity scores were
normalized into values of a range of 0-1 using min-max normalization using equation (1):
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑠𝑐𝑜𝑟𝑒 =

𝑥 − min(𝑥)
max(𝑥) − min(𝑥)

(1)

where 𝑥 is a patient’s total score while min(𝑥) 𝑎𝑛𝑑 max(𝑥) are the minimum and
maximum scores of the scales.
Table 2 Medication information of patients in the NeuroCog study

Antipsychotic DDDs
(mean ± SD)
Received
antipsychotics or not
1st Generation
Trifluoperazine
Zuclopenthixol
Flupentixol
Haloperidol
Fluphenazine
Perphenazine
Aripiprazole

Schizophrenia (n =
44)
1.33 ± 0.92

Schizoaffective (n =
29)
1.24 ± 0.79

Patients (n = 73)

Yes: 36
No: 2
6
1
1
2
0
1
1
0

Yes: 26
No: 0
5
1
0
0
1
1
1
1

Yes: 62 (85%)
No: 2 (3%)
11 (15%)
2
1
2
1
2
2
1

1.30 ± 0.87
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2nd Generation
Risperidone
Olanzapine
Clozapine
Quetiapine
Ziprasidone
Combination
Received depot
injection
Received
antidepressants
Received
Benzodiazepine
Unknown
medication history

Schizophrenia (n =
44)
22
5
4
10
2
1
8
5

Schizoaffective (n =
29)
14
4
4
4
0
2
7
9

Patients (n = 73)

Yes: 18
No: 20

Yes: 15
No: 11

Yes: 33 (45%)
No: 31

Yes: 15
No: 23
6

Yes: 12
No: 14
3

Yes: 27 (37%)
No: 37
9 (12%)

36 (49%)
9
8
14
2
3
15 (21%)
14 (19%)

2.3.2 Clustering Solution and Composition
A visual inspection of the agglomerative hierarchical cluster analysis dendrograms
(Figures 1A-1B) suggested that subtyping solutions of 2 to 8 clusters could be
meaningful. Subsequently, the NbClust function in R (Charrad et al., 2014) was used to
compute 16 external validity indices for two- to eight-cluster solutions, respectively. The
output showed that a two-cluster consistently received the highest number of votes
(Neurocog: 10/16; CONN: 6/16; Figures 2A-2B). The same clustering procedure was reapplied to the patient samples only, and a two-cluster solution was again the most
favoured solution (Figure 3A-3B). Out of the 53 patients identified as cortically
impoverished with whole-sample approach, 48 patients were correctly identified with
patient-only approach, providing a subgroup-level accuracy of 90% (Table 3). A twocluster solution was chosen based on the majority consensus.
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(A) NeuroCog ‘Discovery’ Dataset

(B) CONN ‘Validation’ Dataset

Figure 1 Hierarchical cluster dendrogram of the ‘Discovery’ and ‘Validation’ samples

(A) NeuroCog ‘Discovery’ Dataset

(B) CONN ‘Validation’ Dataset

Figure 2 Bar plots of the frequency of proposed cluster solutions, when clustering
with patients and healthy controls.
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(A) NeuroCog ‘Discovery’ Dataset

(B) CONN ‘Validation’ Dataset

Figure 3 Bar plots of the frequency of proposed cluster solutions, when clustering
with patients only.
Table 3 ‘Cortical impoverishment’ subgroup membership when clustering is carried
out with or without the data from healthy controls.
NeuroCog ‘Discovery’ Dataset

SCZ-only clustering

Patients only

Cortical

Non-impoverished

Impoverishment
Whole sample

Cortical

clustering

Impoverishment
Non-impoverished

35

5

3

30

CONN ‘Validation’ Dataset

SCZ-only clustering

Patients only

Cortical

Non-impoverished

Impoverishment
Whole sample

Cortical

clustering

Impoverishment
Non-impoverished

13

0

16

12
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With a two-cluster solution, the proportion of patients (Figures 4A-4B) varied
significantly across clusters [NeuroCog: χ² (N = 136) = 15.186, p < 0.0001; CONN: χ²
(N = 81) = 20.128, p < 0.0001], revealing a subgroup (Cluster 1) with mostly patients.
The proportion of patients relative to healthy controls within Cluster 1 was 75.5% and
100% in NeuroCog and CONN samples, respectively. A larger second cluster comprised
a relatively balanced ratio of patients and controls, with patients accounting for 40% and
41% in the two datasets.

Figure 4 Distribution of patients and healthy controls in the two thickness-based
clusters in the two studies.

2.3.3 Neuroanatomical Differences Between Clusters
Multiple t tests with Bonferroni correction were conducted to examine differences
between clusters. A consistent pattern of cortical thinning was observed in Cluster 1 (see
vertex-wise comparison in Figure 5); Number of cortical regions that were significantly
thinner in Cluster 1 after correction: 100/148 in NeuroCog and 11/148 in CONN).
When examining patients only, 44/148 regions in NeuroCog and 7/148 regions in CONN
showed significantly thinner cortex among Cluster 1 patients (p <0.01 after Bonferroni
correction; See Table 4 for the top 5 cortical regions and cortical thickness maps that
showed significant differences in each sample), with none of the cortical regions showing
a significantly higher thickness among cluster 1 patients. To investigate whether patients

20

and controls clustered together indeed had similar thickness patterns, we also compared
patients and controls in terms of cortical thickness values in Cluster 2 which had a
relatively balanced patient/control ratio. The results showed no significant differences in
any of the anatomical regions after multiple-testing corrections across all three samples.

‘NeuroCog’ Discovery Dataset (Cluster 1 N = 49; Cluster 2 N = 67)
Left Hemisphere
Anterior View

Posterior View

Medial View

Right Hemisphere
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‘NeuroCog’ Discovery Dataset (Cluster 1 N = 49; Cluster 2 N = 67)
Lateral View

Figure 5 Cortical thickness maps of differences between members of the two clusters
in the discovery dataset.
Note: The cluster membership is irrespective of diagnostic status (i.e, both patients
and control subjects are included). Only the cortical surfaces generated by
FreeSurfer (regressing out age effect with general linear model, uncorrected)
without any need for manual editing are included in this vertexwise analysis. Scale
indicates log10 of p-values and cortical regions with p-values > 0.01 were
highlighted. Blue/cyan colours indicate Cluster 1 < Cluster 2 while red/yellow colour
indicate Cluster 2 < Cluster 1. Cluster 1 is the ‘cortical impoverishment’ group that
shows a globally distributed thickness reduction compared to Cluster 2.

Table 4 Top 5 cortical parcellations that showed largest effect sizes in thickness
between patients of the two clusters.
NeuroCog sample

CONN sample

R superior frontal gyrus

R planum temporale or temporal plane of

R middle posterior cingulate gyrus and

the superior temporal gyrus

sulcus

L planum temporale or temporal plane of

L superior frontal gyrus

the superior temporal gyrus

R paracentral gyrus and sulcus

L superior temporal sulcus

R middle frontal gyrus

L supramarginal gyrus
L precentral gyrus
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2.3.4 Characteristics of Participants in Each Cluster
2.3.4.1

Cognitive Characteristics

In the NeuroCog Sample, there was no significant difference between patients in the two
clusters in WASI IQ estimate and MCCB composite scores, but healthy controls of the
two subgroups differed significantly on these two cognitive measures (Figure 6A-6B).
Results from examining differences between patients and controls within the clusters
showed that patients were cognitively indistinguishable from the controls in Cluster 1
(MCCB: patients M[SD]= 29.18[14.1] vs. controls M[SD]= 33.46[13.3]; p = 0.33), while
patients in Cluster 2 were more cognitive impaired than controls in the same subgroup
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(MCCB: patients M[SD] = 29.36[11.69] vs. controls M [SD]= 43.44[13.95]; p < 0.0001).
The seven cognitive domains were separately examined (see Figure 6C).

(A)

(B)

Figure 6 Comparisons of cognitive characteristics
of members in each cluster in the
(C)
NeuroCog 'Discovery' Sample.
Note: (A) WASI: Wechsler Abbreviated Scale of Intelligence; (B) MCCB:
MATRICS (Measurement and Treatment Research to Improve Cognition in
Schizophrenia) Consensus Cognitive Battery; (C) Seven cognitive domain scores
from MCCB of patients in each cluster. MCCB Composite and domain scores are
standardized as T-scores with a mean of 50 and a standard deviation of 10.
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2.3.4.2

Clinical Characteristics

Comparison of patients between clusters showed no significant difference in overall
symptom severity measured by PANSS in the NeuroCog (Figure 7A), but in the CONN
study, there was a significant difference between the two clusters in the severity of
symptoms measured by SSPI (Cluster 1 > Cluster 2; p = 0.016; Figure 7B). There was no
significant difference in antipsychotic medication (Figures 7C-7D) or duration of illness
(Figures 7E-7F) in both the discovery and the CONN validation dataset. There was no
significant difference in functioning between patients of the two clusters, which was
measured by COALS or SOFAS (Figures 7G-7H).
NeuroCog ‘Discovery’ Dataset

CONN ‘Validation’ Dataset

Symptom
Measures

(A)

(B)

(C)

(D)

(E)

(F)

Antipsychotic
Medication
Dose

Illness
Duration
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NeuroCog ‘Discovery’ Dataset

CONN ‘Validation’ Dataset

Functional
Outcome

(G)

(H)

Figure 7 Comparisons of clinical characteristics of patients in each cluster.
Note: (A) 30-items Symptom severity of patients in NeuroCog sample measured by
Positive and Negative Syndrome Scale (PANSS); (B) Symptom severity of patients
in CONN sample measured by Signs and Symptoms of Psychotic Illness (SSPI); (CD) Antipsychotic medication defined daily dose (DDD) calculated according to
World Health Organization. (E-F) Duration of illness measured in years. (G)
Independent living skills measured by Canadian Objective Assessment of Life Skills
(COALS) in the NeuroCog sample; (H) General functioning measured by SOFAS in
the CONN sample.

2.3.5 Exploratory Analysis of Symptoms, Cognition and Medication
In the Discovery Dataset, cognitive deficits did not show a significant relationship with
positive symptom severity in either subgroup (Figure 8A). However, cognitive
performance was significantly reduced in patients with more severe negative symptoms
in Cluster 1 (r = -0.46, p = 0.0032), but not in Cluster 2 (Figure 8B). Negative symptomcognition correlation coefficients were significantly different between subgroups (z = 2.234, p = 0.013).
Both illness severity and antipsychotic medication dose have been implicated in cortical
thickness changes in schizophrenia (Andreasen et al., 2013; Lepage et al., 2020). We
examined whether both thickness-based subgroups of patients had the same relationship
between higher doses of antipsychotics and higher symptom severity. There was no
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correlation between antipsychotic exposure and overall or positive symptom burden in
Cluster 1 or Cluster 2 (Figure 8C-8F), but an increase in antipsychotic exposure was
associated with different directions of change in negative symptom severity in Cluster 1
and Cluster 2 (z = -1.987, p = 0.023; Figure 8E).
Additionally, antipsychotic exposure and cognitive abilities were not significantly
associated (Figure 8G), and the two subgroups did not show a difference in this
relationship (z = -0.687, p = 0.246).

(A)

(C)

(B)

(D)
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(F)

(E)

(G)
Figure 8 Relationships between cognitive test scores, symptoms severity
measurements and antipsychotics defined daily dose in Cluster 1 and Cluster 2
patients, respectively in the NeuroCog ‘Discovery’ Sample.
Note: MCCB, MATRICS (Measurement and Treatment Research to Improve
Cognition in Schizophrenia) Consensus Cognitive Battery; PANSS: Positive
and Negative Syndrome Scale; DDD, defined daily dose calculated according to
World Health Organization.
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2.4

Discussion

2.4.1 Discovery and Validation of Two thickness-based subgroups
We identified two subgroups based on cortical thickness profiles across the whole brain.
The two subgroups differed in the proportion of ‘cortical normality’ indicated by the
amount of variance shared with healthy controls. One subgroup displayed reduced
thickness or impoverishment and the majority of the members in this subgroup were
patients with schizophrenia. The remaining patients had more typical or spared thickness
patterns. The neuroanatomical differences between the two clusters varied across the two
samples, possibly due to differences in recruitment criteria as well as the sample size
differences, which combined with our stringent correction for multiple testing, reduced
the likelihood of demonstrating significant regional differences in validation sample.
Furthermore, the presence of stage-specific differences in the location of grey matter
differences (i.e., the duration of illness effect) from age- and sex-matched healthy cohorts
is a well-established finding in schizophrenia (M. Li et al., 2022; Palaniyappan, 2017).
While scanning parameters varied across the two studies, it is important to note that both
patients and healthy controls were scanned using the same acquisition parameters within
each study. Further, we did not see any notable variations in the global estimates of
cortical thickness across the two studies.
Previous cluster analytic studies based on cortical thickness generally selected one
clustering validation method to determine the optimal number of clusters (Pan et al.,
2020b; Sugihara et al., 2017b). However, we demonstrated that the number of clusters
depends on the selection of validity indices. A variety of cluster solutions were deemed
meaningful in our three datasets, which could partially explain the inconsistency in the
number of clusters reported in the literature (see Figure 2 and 3). Instead of cluster
selection based on a single validity measure, the application of multiple validation indices
allows for convergence to a final and consensual cluster solution.
Our two-cluster solution resembles Type I and Type II schizophrenia proposed by Crow
(Crow, 1980). Crow anticipated pronounced brain structural abnormalities in one group
(in line with our cortical impoverishment subgroup), referred to as Type II of
schizophrenia, but not the other (Crow, 1980). However, in a later version, Crow
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admitted the possibility that the two subtypes he proposed may indeed be two
distinguishable dimensions of illness that might coexist in an individual case (Crow,
1985). More recently, Chand and colleagues uncovered a strikingly similar two-cluster
solution by clustering on the grey matter volume of patients. Despite the differences in
the statistical approach and variable selection (thickness vs. volume), they also reported a
lack of clinical and demographic differences between the two subgroups (Chand et al.,
2020b).

2.4.2 Aggregation of patients and controls
A sizeable number of IQ-matched healthy controls (nearly one-fifth) in the discovery
dataset were part of the subgroup with thinner cortex. Thus, the differences among
healthy individuals may contribute, in part, to the reported variability in effect sizes from
case-control studies, reducing the ability to discriminate a patient from a non-patient
based on the brain structure (Greenstein et al., 2012; Takayanagi et al., 2011).
It is worth noting that around half of patients had thickness patterns that were
indistinguishable from the majority of healthy participants, indicating that processes that
disrupt cortical morphology do not operate across all patients with schizophrenia. This
pattern argues against the presence of a detectable anatomical signature across the whole
brain to describe the neurodevelopmental or neurodegenerative nature of schizophrenia.
Crow also argued that the lack of structural brain changes in the ‘Type I’ syndrome of
schizophrenia is reflective of a hyperdopaminergic process, producing reversible features
of an acute, positive-symptom-dominated profile with intact cognition (Crow, 1985). A
lack of prominent structural changes in a majority of patients may also result from
compensatory processes that lead to structural reorganization in the post-onset period
(Palaniyappan, 2019). If cortical reorganization with time is a relevant process, it raises a
question regarding the stability of subgroup membership. Longitudinal studies are
required to parse this issue.

2.4.3 Similarities between the two thickness-based subgroups
Irrespective of brain structural differences between the subgroups, a feature that is
conspicuous by its absence is the lack of significant clinical and cognitive differences
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between the patients of the two subgroups. This lack of clinical differences among
structural MRI-based subgroups has been reported in several other studies (Chand et al.,
2020b; Dwyer et al., 2018b; Pan et al., 2020b; Planchuelo-Gómez et al., 2020). Although
some studies have related a longer illness duration (Dwyer et al., 2018b; Pan et al.,
2020b; Planchuelo-Gómez et al., 2020) and higher medication exposure (Pan et al.,
2020b; Sugihara et al., 2017b) to more extensive cortical thinning, we did not find these
associations in our data. Age differences between subgroups likely accounted for these
differences in those previous studies (Dwyer et al., 2018b; Pan et al., 2020b; PlanchueloGómez et al., 2020).
In our discovery dataset, cognitive differences were found among healthy controls
between the 2 subgroups, in line with prior data (Deary et al., 2010), but between the two
subgroups, patients did not differ on their IQ or MCCB test scores. This implies that
although poor cognitive performance is associated with cortical thinning in healthy
people, developmental influences that result in impaired cognition in schizophrenia are
unrelated to processes associated with impoverished cortex. This result is discrepant with
studies that report cognitive impairment as a correlate of compromised cortical structural
integrity in schizophrenia (Hartberg et al., 2011; Alkan et al., 2021). Cluster analytics
studies that dissected heterogeneity in the cognitive feature space generally found
subtypespecific neuroanatomical signatures (Cobia et al., 2011; Geisler et al., 2015;
Ivleva et al., 2017; Weinberg et al., 2016). Similarly, in a cluster analysis based on
cortical thickness, surface area and subcortical volume, Xiao et al. (2021) found that the
cluster with widespread grey matter and subcortex deficits exhibited a significant
impairment in cognition compared with patients with minimal or no significant brain
alterations. The cognitive similarity between the two thickness-based subgroups of
patients in our study does not negate the discriminative ability of other brain features (for
example, white matter or subcortical volume, or connectivity (Kelly et al., 2019; Wexler
et al., 2009) in identifying cognition-based clusters. However, our finding is in line with
recent proposals that several disease-associated factors (i.e., psychological, symptomatic
and social factors) likely contribute to cognitive dysfunction (Moritz et al., 2017, 2020),
and it is possible that among patients, these factors are not differentially distributed on
the basis of grey matter thickness alone.
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Overall, our results suggest that the illness duration and cognitive deficits do not vary
with cortical thickness across the whole brain in schizophrenia. If cortical
impoverishment lies on the causal mechanistic pathways to schizophrenia, then the lack
of notable clinical differences supports the argument that similar ‘phenocopies’ may
emerge from distinct mechanisms.

2.4.4 Differences between the two thickness-based subgroups
The only group-level difference in clinical features between the 2 clusters in our analysis
came from the CONN ‘Validation’ dataset where patients with ‘cortical impoverishment’
displayed a more severe total symptom burden than other patients. In essence, this meant
that the variation in SSPI total score across the patients in CONN sample represented the
variability in symptoms that persisted despite treatment that provided a degree of clinical
stability. Thus, cortical impoverishment may determine symptom persistence, rather than
the acute severity. This is consistent with indistinguishable acute presentations, despite
diverging inter-episode clinical patterns in schizophrenia (Jablensky, 2006a). Other
phenotypic information such as the degree of treatment resistance and the time taken to
respond to the treatment were not available to us, but these may be of interest in future
studies of thickness.
Another difference between the two patient subgroups involved the correlations between
negative symptom severity, cognitive deficits, and medication dosage. The relationship
between cognitive deficits and negative symptoms is considered a central feature of
schizophrenia that influences poor long-term functioning (Strassnig et al., 2015; Ventura
et al., 2009). Our results indicated a relationship between negative symptom severity and
cognitive impairment in patients with cortical thinning, but not in patients with nearnormal thickness. Patients with cortical impoverishment displayed a co-occurring pattern
of cognitive deficits and negative symptoms. In contrast, the cortically spared group had
a notable dissociation between cognitive deficits and negative symptoms. The shared
variance between negative symptoms and cognitive deficits is a well-established feature
of schizophrenia (Harvey et al., 2006); our findings indicate that structural deficits may
influence this reported relationship. Thus, structural heterogeneity may affect the
covariance among symptom domains (negative/cognitive), rather than simply changing
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the overall severity of clinical features. We also noted a dissociation between negative
symptom severity and the prescribed doses of antipsychotics in the 2 clusters, although
the antipsychotic dose had no significant relationship with symptoms or cognitive deficits
in either cluster. To ascertain if the treatment response of the 2 subgroups differs,
especially in the domain of negative symptom severity, larger samples with data on
cumulative antipsychotic exposure are required.

2.4.5 Limitations
Our study has several strengths, including the recruitment of an IQ-matched patient and
control group, and validation of the initial cluster solution in a validation sample with
different illness duration. While the healthy subjects in our discovery sample (group
matched for IQ with patients) likely differed from their peers in the validation sample,
majority of healthy controls in each of the 2 samples aggregated within the structurally
unimpaired subgroup. This indicates that over-sampling cognitively underperforming
healthy subjects has not introduced systematic errors in the retrieved cluster structure and
composition. Some limitations also require consideration. First, the multivariate patterns
that separated the two subgroups in one dataset cannot be re-applied to other samples.
Second, we lacked prospective data to confirm the stability of the reported clusters.
Third, we are not able to conclude with certainty that the number of thickness-based
clusters is limited to two, as increasing the sample size may capture more sources of
variance that are missing in our current sample, but may yield further partitions within
the patient group. Finally, despite our best efforts, the proportion of female participants
remained lower than optimal. We urge caution when readers attempt to generalize our
findings to mixed samples.
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Chapter 3

Cortical Impoverishment Subgroup in Firstepisode Psychosis

Symptoms of schizophrenia are closely related to aberrant language comprehension and
production. In this Chapter, we aimed to first seek patient subgroups with different
neurobiological signatures and then quantify linguistic indices that capture the symptoms
of “negative formal thought disorder” (i.e., fluency, cohesion, and complexity of
language production). We characterized a patient subgroup with thinner cortex in firstepisode psychosis. This subgroup, identifiable through macroscopic changes, is also
distinguishable in terms of neurochemistry (frontal glutamate) and language behavior
(complexity and cohesion of speech). This study supports the hypothesis that glutamatemediated cortical thinning may contribute to a phenotype that is detectable using the tools
of computational linguistics in schizophrenia. This chapter was adapted from the
manuscript published on Frontiers in Human Neuroscience 2.

3.1

Introduction

3.1.1 Language Deficits in Schizophrenia
Schizophrenia is a disorder that affects how language is employed in everyday use during
social interactions (Covington et al., 2005; Kuperberg, 2010; Wible, 2012). Based on the
Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) (American
Psychiatric Association, 2013), all of the 5 symptom criteria for diagnosing schizophrenia
involve speech and language in one form or another (American Psychiatric Association,
2013). For example, hallucinations are often voices that speak (Alderson-Day et al.,
2021); negative symptoms are characterized by ‘alogia’ or reduced speech fluency;
thought disorder is expressed as deviations in speech; catatonic features often include
mutism (lack of speech production) (Sims’ Symptoms in the Mind: Textbook of

2

A version of this chapter has been published on Frontiers in Human Neuroscience (Liang, Silva, et al.,
2022)
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Descriptive Psychopathology - 7th Edition, n.d.); delusions often include an element of
misinterpretation of social conversations or deficits in the use of propositional language
(Zimmerer et al., 2017). Despite this strong linguistic dependency of the construct of
schizophrenia, not every patient diagnosed with this illness displays a detectable speech
disturbance (Kircher et al., 2018a; Oomen et al., 2022; Roche et al., 2015). It is important
to identify patients who are most likely to be afflicted in the language domain, as speech
disturbances directly affect the educational and occupational success (Palaniyappan et al.,
2019), interpersonal (Tan et al., 2014) and social functioning (Marggraf et al., 2020) and
endured stigma (Penn et al., 2000). Identification of this subgroup may assist in
prognostication in schizophrenia, as well as making early and targeted interventions for a
group that may have higher educational and vocational needs possible, before they
manifest significant deficits in these domains.

3.1.1.1

Computational Measures of Language Deficits

The heterogeneity of linguistic deficits may stem from the presence of a subgroup of
patients who do not display the expected language anomalies (Oomen et al., 2022).
Alternatively, conventional measures of ‘formal thought disorder (FTD)’ that seek to
examine overt communication difficulties may miss the subtle aspects of this deficit, thus
introducing an apparent heterogeneity (Mikesell & Bromley, 2016). We need sensitive and
objective measures of language indices to study this issue in detail (See Elvevag et al.
(Elvevåg et al., 2010; Holmlund et al., 2020) and Foltz et al. (Foltz et al., 2016) for more
explanations). One of these tools is natural language processing (NLP) in computational
linguistics (Corcoran et al., 2020; Corcoran & Cecchi, 2020; Hitczenko et al., 2021;
Ratana et al., 2019). NLP tools use computer algorithms to understand and analyze
written text or speech. NLP is a branch of artificial intelligence that uses real-world
language as input, processes it using linguistic rules or patterns identified through
statistics, to allow machines to make sense of our language. Such NLP tools do not rely
on a clinician’s inferential skill to assess the cognitive-linguistic health status (Voleti et
al., 2020) of patients from early stages of psychosis (Delvecchio et al., 2019) and are able
to predict psychosis onset in individuals at clinical high-risk (CHR) (Bedi et al., 2015).
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These approaches have broadly focused on syntactic (Covington et al., 2005; Delvecchio
et al., 2019; Thomas, 1996; Thomas et al., 1990) and semantic indices (Alonso-Sánchez
et al., 2022; Bar et al., 2019; Corcoran et al., 2018; Parola et al., 2022) as the affected
domains in psychosis.
Prior studies that focused on quantitative analysis of language have established the
following dysfunctions in patients with schizophrenia. First, patients display syntactic
simplification (Bilgrami et al., 2022; DeLisi, 2001; Fraser et al., 1986; King et al., 1990; R.
D. Morice & Ingram, 1982, 1983; R. Morice & McNicol, 1986) i.e., they use simple
constructions with minimal clause dependencies and also with a limited richness of
content. Secondly, patients show patterns of reduced cohesion (Crider, 1997), for
example, lacking prior reference when invoking a description (Chaika & Lambe, 1989) or
insufficient lexical repetitions (Gupta et al., 2018) needed to generate cohesion during a
discursive discourse (Crossley et al., 2016). Reduced syntactic complexity and cohesion
can lead to aberrant word graphs (Mota et al., 2012) and a reduction in number of words
spoken (reduced fluency) (Allen et al., 1993; DeLisi, 2001; Morgan et al., 2021).

3.1.2 Detecting Subgroups with Language Dysfunctions
While some of these features have been linked to the presence of clinically detected FTD,
the rating-scale measures of FTD have been poor predictors of linguistic dysfunction per
se (Mackinley et al., 2021; Tang et al., 2021). Furthermore, as symptom measures
fluctuate over time (state-like), they have limited utility in identifying stable subgroups
(Jablensky, 2006b). Even among speech characteristics, those that relate to ‘positive
symptoms’ appear to be more state-related, while those relating to negative symptoms (or
Impoverishment of Thinking (Liddle, Ngan, Caissie, et al., 2002b)) appear to be more
pervasive. More trait-like measures, e.g., those derived from brain anatomy or genetic
composition, that map on to emerging biological insights (e.g., implicating the
glutamatergic synapses (Iyegbe & O’Reilly, 2022; Trubetskoy et al., 2022)), may be
required to see if specific subgroups of patients have linguistic deficits. Furthermore, as
antipsychotics themselves can induce language impairment (de Boer et al., 2020),
recruitment of patients with first-episode psychosis with minimal exposure to
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antipsychotic medications is necessary to identify subgroups with language dysfunction
from illness onset.

3.1.2.1

Cortical thickness-based Subgroups

In the current study, we first identify subgroups of patients with first-episode
schizophrenia using the neuroanatomical measure of MRI-derived cortical thickness.
Structural neuroanatomical features are considered to be more stable than symptom rating
and physiological recordings, which can vary on a day-to-day basis. In addition, MRIderived thickness is quantified objectively in an automatized manner with minimal
manual intervention in the quantification process. Thus, brain structure can provide more
stable and reliable clustering solutions. Further, aberrant cortical thickness has been
reported in various illness stages of schizophrenia (Zhao et al., 2022), and has been also
found to relate to track the inter-individual differences in psychotic symptoms (OertelKnöchel et al., 2013) and Thought and Language Disorder scores in schizophrenia
(Palaniyappan et al., 2020). Prior cluster analytic studies have uncovered a consistent
cluster of patients with generalised reduction in cortical thickness (Chand et al., 2020a;
Dwyer et al., 2018a; Liang, Heinrichs, et al., 2022). We use similar methods in this study.

3.1.3 Cortical thickness and Glutamate
After deriving thickness-based subgroups, we examined if these subgroups have a
meaningful neurochemical basis for their differences, by examining the MRS-derived
glutamate levels measured from their frontal cortex, extending our recent work (Liang,
Heinrichs, et al., 2022) to a larger sample.
Abnormal cortical thickness in schizophrenia has been previously linked to dysregulated
glutamate levels (Plitman et al., 2014, 2016; Shah et al., 2020) and glutamatergic
dysfunction had been considered to contribute to the ‘formal thought disorder’ burden in
schizophrenia (Kircher et al., 2018a). We select dACC as our region of interest for
glutamate measurement as it constitutes the core hub of the large-scale brain network
called the Salience Network that appears to play a key role in the neurocognitive
dysfunction in schizophrenia (Palaniyappan, 2021b).
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3.1.4 Negative FTD-related Language Features
Finally, we used a picture description task to study computational linguistic measures that
are reflective of a “negative” formal thought disorder, first described by Fish (Casey &
Kelly, 2019) and later reported by Andreasen (Andreasen, 1979) and others (Kircher et al.,
2018a) as being more characteristic of established schizophrenia. Negative FTD is
characterized by reduced quantity and quality of speech output; in a linguistically
impoverished subgroup, this will be reflected in (i) reduced fluency (number of words
spoken), (ii) reduced cohesion (measured by counting instances of content with prior
reference, i.e. repeat content lemmas, e.g., run, running and ran), and (iii) reduced
syntactic complexity (mean length of sentences, clauses and minimal terminable units [Tunits, the smallest word group that could be considered a grammatical sentence, often
composed of a main clause and subordinate clauses attached to it (Hunt, 1970)]).
While there are numerous quantitative linguistic measures reported to be different in
case-control comparisons, we chose items that predominantly map onto the negative
symptom domain of schizophrenia (Bilgrami et al., 2022; Tan et al., 2021), independent of
corpus-based distributional probabilities (which has limitations in understanding
compositionality (Lenci, 2018) - a crucial locus of dysfunction in schizophrenia (Chaika,
1974)) and are readily interpretable (e.g. we did not use referential cohesion measure
which is conflated in the presence of perseveration (Lundin et al., 2020)). The features we
selected are also intuitive in their link to known clinical features (reduce word count
relates to alogia; lack of cohesion and simplified syntax relates to the poverty of content
(Bedi et al., 2015; Corcoran et al., 2018; Minor et al., 2019)). Furthermore, compared to
other aspects of communication disturbances, the features of reduced fluency and
richness of content (negative factor) selectively relate to poor response to treatment
(Peralta et al., 1992). A neuroanatomically-defined subgroup high in these ‘negative FTD
type’ linguistic features can be expected to be of prognostic relevance in schizophrenia.

3.1.5 Hypotheses
Considering previous structural imaging-based cluster analytic studies, our primary
hypothesis is that patient subgroups with distinct cortical thickness patterns can be
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identified in first-episode schizophrenia. In particular, a subgroup with widespread
cortical thinning would emerge. Considering the association between cortical thinning,
dysregulated glutamate levels and formal thought disorder burden, our secondary
hypotheses are as follows: (i) The subgroup with deviant cortical thickness patterns also
has abnormal glutamate levels measured in dACC; (ii) This subgroup displays
impairments (negative FTD-type) in language production features, such as syntactic
simplicity, reduced speech output and lower speech cohesion.

3.2

Methods

3.2.1 Participants
We recruited 76 patients with first-episode psychosis from the Prevention and Early
Intervention for Psychosis Program at the London Health Sciences Centre in London,
Ontario, Canada from 2017 to 2021. Since 10 patients were unable to go through
magnetic resonance imaging (MRI) scanning, we included data collected for 66 patients
in this study. Inclusion criteria for patients include (1) having less than 14 days of
lifetime exposure to antipsychotic medications, and (2) being at their first clinical
presentation of psychotic symptoms. We followed up with patients for over 6 months to
determine the validity of a diagnosis of first-episode schizophrenia prospectively. We
also recruited 36 healthy volunteers, group-matched for age, sex, and parental
socioeconomic status, who had no personal history of mental illnesses and no family
history of psychotic disorders. All participants had no significant head injury,
drug/alcohol dependence or major medical illnesses, were fluent in English, and provided
written informed consent to participate in the study. The work reported here is part of a
longitudinal study registered on clinicaltrials.gov (Identifier: NCT02882204) and
approved by the Western University Health Sciences Research Ethics Board, London,
Ontario, Canada.
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3.2.2 Measures and instruments
3.2.2.1

Psychiatric Symptoms

Symptom severity was measured by the 8-item Positive and Negative Syndrome Scale
(PANSS) (C.-H. Lin et al., 2018) through interviews conducted by two research
psychiatrists. Functional outcome was indexed by the Social and Occupational Functional
Assessment Scale (SOFAS) (Morosini et al., 2000b). The duration of untreated psychosis
was calculated using the first report of positive symptoms as the starting point. We also
obtained patients’ NEET (Not in Education, Employment and Training) status. We
converted participants’ level of education into an ordinal scale (1: incomplete high school
diploma; 2: completed high school diploma; 3: some post-secondary study; 4: completed
post-secondary study or higher). Lifetime antipsychotic medication exposure was
calculated by multiplying the number of days taking antipsychotics and prescribed
Defined Daily Dose (DDD) values according to the World Health Organization (Defined
Daily Dose (DDD), n.d.).

3.2.2.2

Thought and Language Index (TLI)

Data was collected using TLI (Liddle, Ngan, Caissie, et al., 2002b) to reflect the two
dimensions of language disorders in schizophrenia, impoverishment and disorganization.
We used a picture-speech task that induced participants to elaborate 1-min spontaneous
speech (oral soliloquies) in response to three images from the Thematic Apperception
Test (Murray, 1943) after hearing specific instructions: “I am going to show you some
pictures, one at a time. When I put each picture in front of you, I want you to describe the
picture to me, as fully as you can. Tell me what you see in the picture, describe what you
see in this image, and what you think might be happening.” Responses were recorded,
transcribed, and scored. Impoverishment score was the sum of scores for these 3
dimensions: poverty of speech, weakening of goal and preservation of ideas, while
disorganization score was indexed by 5 dimensions: looseness, peculiar use of words,
peculiar sentences, peculiar logic, and distractibility.
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3.2.2.3

Language assessment

The same transcribed speech samples also underwent automatic analysis to measure both
syntactic complexity and cohesion at the semantic level.

3.2.2.3.1

Tool for the automatic analysis of syntactic complexity
and sophistication (TAASSC)

TAASSC is an open-source (https://www.linguisticanalysistools.org/taassc.html) used in
wide-ranging languages and grammatical frameworks with recent improvements in
machine-learning approaches and Natural Language Processing (NLP). This tool is
complemented by a syntactic complexity analyzer (SCA)—a package with an accuracy of
around 90% in part of speech (POS) tagging. The package includes a traditional and large
measure of syntactic complexity following the taxonomy in Lu (2010) (Lu, 2010): mean
length of sentences (MLS), mean length of T-units (MLT) and mean length of clauses
(MLC), word counts, and Terminal Units (T-unit) defined as the main clause with its
attached subordinate clause(s) indicating speech cohesion as well as logical flow in the
given information (See Supplementary Material for more detailed descriptions).

3.2.2.3.2

Tool for the Automatic Analysis of Cohesion (TAACO 2.0)

TAACO 2.0 (https://www.linguisticanalysistools.org/taaco.html) (Crossley et al., 2016)
is a freely available text analysis tool which incorporates a wide-ranging of global
indices— over 150 classic and recently developed indices related to text cohesion—local,
global, and overall text cohesion can significantly predict both text cohesion and
speaking quality whether the speaking samples show greater semantic overlap
incorporating automated semantic analysis (Crossley et al., 2019). TAACO includes 194
indices of cohesion in seven main categories: Type token ratio (TTR) and density, lexical
overlap (sentences), lexical overlap (paragraphs), semantic overlap, connectives,
givenness, and source text similarity. Of this, we focus on the givenness index as we
analyze speech rather than written text. Givenness, as opposed to newness in a discourse
transcript, indicates whether information occurring in a segment has already occurred in
an earlier segment. Repeat content words or lemmas (e.g., nouns, verbs, adjectives, etc.)
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are calculated as a proportion of the total number of words spoken within each 1-minute
picture description.

3.2.3 MRI and MRS Acquisition and Processing
A total of 66 participants underwent neuroanatomy and spectroscopy scanning with an
ultra-high-resolution 7-Tesla MRI scanner (8-channel transmit and 32-channel receive
head-only coil) at Centre for Functional and Metabolic Mapping (CFMM), Western
University, London, Canada. Structural images were obtained by a T1-weighted 0.75 mm
isotropic MP2RAGE sequence with the following parameters: Repetition Time (TR) =
6000 ms, Time to Echo (TE) = 2.83 ms, Inversion Time (TI)1 = 800 ms, TI2 = 2700 ms,
flip-angle 1 (α1) = 4°, flip-angle 2 (α2) = 5°, Field of View (FOV) = 350 mm × 263 mm ×
350 mm, Tacq = 9 min 38 s, iPATPE = 3 and 6/8 partial k-space, slice thickness = 0.75mm.
Freesurfer (version 6.0.0) (FreeSurfer, n.d.) was used to preprocess the obtained T1weighted images. FreeSurfer provides automated brain image processing steps including
intensity normalization, tissue segmentation and cortical parcellation (Recon-All - Free
Surfer Wiki, n.d.). Visual inspections of errors such as surface location misplacement
were carried out according to the troubleshooting guide provided by FreeSurfer team
(FsTutorial/TroubleshootingData - Free Surfer Wiki, n.d.). We acquired the cortical
thickness values based on the Destrieux parcellation atlas (Destrieux et al., 2010b).
Magnetic resonance spectroscopy (MRS) signal was measured on a voxel placed in the
dorsal anterior cingulate cortex (dACC; MNI coordinates: 1, 16, 38). The details of MRS
acquisition and analysis have been previously described (See Supplementary Material)
and a subset of this sample has been reported in prior works (Jeon et al., 2021; Liang,
Heinrichs, et al., 2022).

3.2.4 Statistical Analyses
We applied agglomerative hierarchical clustering with Ward’s method and Euclidean
distance to 148 cortical thickness values (based on Destrieux parcellation atlas (Destrieux
et al., 2010b) output using FreeSurfer) of all 102 participants including 66 patients and 36
healthy controls. Agglomerative hierarchical clustering starts with calculating the
distance (e.g., Euclidean distance) between all pairs of data objects and putting the most
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similar data objects into the same cluster. The newly formed clusters are then again
grouped with one another based on a linkage function (e.g., Ward’s method), until all
data objects merge into one single cluster. The optimal number of clusters was
determined by the consensus votes from 16 clustering validity indices using NbClust
(Charrad et al., 2014) in R (version 4.0.3). Pearson’s chi-squared tests (with Yate’s
continuity correction) were used to compare categorical variables, while Welch t-tests
were used to compare continuous variables. If the obtained subgroups showed
difference(s) in confounding variables (e.g., age or gender), ANCOVA was used to show
effects between subgroups while accounting for effects of the covariates. We used
FreeSurfer to find (1) between-cluster differences in vertex-by-vertex cortical thickness
while regressing out the effect of age using a general linear model, and to locate (2)
cortical regionals that correlated with glutamatergic metabolic levels. The thickness
values at each vertex were mapped to the surface of an average brain template, and the
cortical map was smoothed with a Gaussian kernel of 10mm full width at half-maximum.
We used Monte Carlo simulations with 1000 permutations and a cluster-forming
threshold of P = 0.05 (two-tailed) to correct for multiple comparisons as implemented in
FreeSurfer.

3.2.5 Sensitivity Analyses
To examine the effects of chosen types of participants, clustering methods and cortical
parcellations on the findings, we performed the following sensitivity analyses (Parpia et
al., 2022) and assessed the robustness of the conclusions.
1) To examine how changing participant type affects the clustering solution: Since
we included both patients and healthy controls in our clustering procedure, there
were naturally two categories of participants and hence a 2-cluster solution could
emerge as a dominant effect. To rule out this possibility, we included only
patients and performed the same clustering procedure.
2) To examine how clustering methods affect the clustering solution: We replaced
the agglomerative hierarchical clustering method with K-means clustering.
Compared to hierarchical clustering that computes pairwise similarity between
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datapoints, K-means clustering holds the assumption that each cluster has a
representative center point, called “centroid”. K-means clustering starts with
randomly selecting a pre-defined number of centroids, and then assigned every
datapoint to its nearest centroids to form clusters. New centroids are then recalculated for the newly formed clusters. This process is iterated until the
centroids do not change. While hierarchical clustering assumes a nested tree-like
data structure, K-means clustering divides datapoints into non-overlapping
subgroups. Participant subgroup assignments from these two different clustering
methods were compared to investigate the effects of chosen clustering method on
results.
3) To examine how cortical parcellation atlas affects the clustering solution: The
cortical parcellation system developed by Destrieux at al. was developed based on
classical neuroanatomical nomenclature (Destrieux et al., 2010b). In contrast to
this brain atlas based on structurally distinct regions, we selected another brain
parcellation system based on functionally distinct regions (Schaefer et al., 2018;
Thomas Yeo et al., 2011). This approach segments the brain into large-scale brain
networks based on functional MRI resting-state functional connectivity (RSFC)
and further maps cortical region boundaries based on homogeneous RSFC
patterns. We used the 7-network (Visual, Somatomotor, Dorsal Attention, Ventral
Attention, Limbic, Default, Frontoparietal Network) atlas with 200 cortical
regions of interest (ROIs), compared to 148 ROIs in the Destrieux atlas (See
Appendix E for cortical parcellation maps).

3.3

Results

3.3.1 Subgroup Characteristics
Demographic, clinical, linguistic, and neurobiological measurements of first-episode
psychosis patients and healthy controls are provided in Table 5.
The cluster validity procedure of hierarchical clustering of 148 cortical thickness values
of 66 patients with first-episode psychosis and 36 healthy controls suggested that a two-
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cluster solution is optimal (9/16 cluster validity indices). Proceeding with a two-cluster
solution, around 70% of patients (n = 46) with first-episode psychosis were clustered
with the majority of the healthy controls (n = 33) in Cluster 1, while the remaining 30%
of patients (n = 20) were in Cluster 2 which only included 3 healthy individuals.
Demographic, clinical, neurometabolite and language functioning information of the
three subgroups (Cluster 1 patients, Cluster 2 patients and Cluster 1 healthy controls) is
summarized in Table 6, and patient subgroups comparisons of key variables are shown in
Figure 9. Overall, compared to Cluster 1 patients, Cluster 2 patients have significantly
older age, lower mean cortical thickens (non-significant age effect), higher glutamate
concentration in dACC (non-significant age effect) as well as lower mean length of Tunits (complexity) and repeated contents lemmas (cohesion) despite a preserved number
of words within the given time frame (fluency). There is no significant difference
between the two clusters in duration of untreated psychosis, lifetime exposure to
antipsychotics, PANSS and SOFAS scores.
Comparisons of cortical thickness between patients from the two subgroups (adjusted for
age) are shown in Figure 10. After multiple testing corrections, patients in Cluster 1 had
significantly lower thickness in 8 clusters (average area size = 410.44 mm2) in the left
hemisphere and right hemisphere respectively (Figure 11 and Table 7). Comparisons of
cortical thickness between the patients and controls from Cluster 1 (adjusted for age and
corrected for multiple comparisons) revealed no regional differences in thickness values,
indicating that this subgroup of patients had a ‘healthy’ cortical morphological pattern.
Multiple cortical regions were correlated with dACC glutamate levels in patients (Figure
12), but these correlations were not significant after multiple testing corrections.
Correlation matrices of other variables of interest are presented in Supplementary
Material.
In summary, patients from Cluster 1 had similar neuroanatomical patterns to healthy
controls, while patients from Cluster 2 were a distinct subgroup with widespread cortical
thinning, higher glutamate concentration, and exhibited and reduced syntactic complexity
and cohesion. This subgroup was thus impoverished in cortical structure as well as
linguistic features.
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Table 5 Demographic, clinical, neurobiological, and linguistic data of patients with
first-episode psychosis and healthy controls
FEP

HC

Pearson’s Chi-squared
test or Welch T-tests
-

N
Demographics
Age (years)

66

36

22.82 (4.77)

Female/Male

12/54

21.53 (3.32) t (94.043) = 1.6005, pvalue = 0.1128
X-squared (1) = 2.1896, p12/24
value = 0.1389

Education Scale
(1/2/3/4)
Clinical
PANSS-8 (Total)
PANSS-8 Positive
PANSS-8 Negative
PANSS-8 General
DUP (weeks)
(median [IQR])
DDD lifetime exposure
(median [IQR])
Antipsychotic naïve
(%)
Functional
SOFAS
NEET status: Yes/No
Neurobiological
Glutamate (mM)
Mean cortical
thickness (mm)
Language Variables
TLI (Total)

15/18/20/13

5/3/14/13

X-squared (3) = 8.0131,
p-value = 0.04574

25.18 (6.72)
11.62 (3.48)
6.97 (4.41)
5.18 (2.46)
11.0 [4, 24]

-

-

-

-

0.5 [0, 2.99]

-

-

42%

40.96 (12.40)
24/29

0/31

6.79 (1.16)

6.51 (1.35)

2.45 (0.12)

X-squared (1) = 17.497, pvalue < 0.0001

***

t (53.766) = 0.99493, pvalue = 0.3242
2.48 (0.096) t (94) = 1.90350, p-value
= 0.0600

1.48 (1.41)

0.29 (0.39)

TLI Impoverishment

0.57 (0.72)

0.14 (0.25)

TLI Disorganization

0.91 (1.21)

0.15 (0.26)

119.18
(38.85)

141.34
(29.83)

Average total number
of words

*

t (81.668) = 6.4188, pvalue < 0.00001
t (87.397) = 4.3669, pvalue < 0.0001
t (75.114) = 4.9033, pvalue < 0.00001
t (88.706) = -3.1775, pvalue = 0.002045

***
***
***
***
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MLS

14.37 (4.58)

14.21 (2.74) t (96.753) = 0.20899, pvalue = 0.8349
MLT
12.21 (3.00)
12.49 (2.08) t (93.295) = -0.56025, pvalue = 0.5767
MLC
7.73 (1.20)
8.19 (1.18) t (73.659) = -1.8858, pvalue = 0.06327
Repeated contents
0.229 (0.047) 0.247
t (89.792) = -2.1269, p*
lemmas
(0.033)
value = 0.03617
Note: Values are reported as “Mean (SD)” unless specified otherwise. IQR: Interquartile
range. FEP: first episode psychosis; HC: healthy controls. PANSS: Positive and Negative
Symptoms Scale; DUP: duration of untreated psychosis; DDD: Defined Daily Dose;
SOFAS: Social and Occupational Functioning Assessment Scale; NEET: not in
employment, education and training; TLI: Thought and Language Index; MLS: mean
length of sentences, MLT: mean length of T-units, MLC: mean length of clauses.
* p values < 0.05
** p values < 0.01
*** p values < 0.001

Table 6 Demographic, clinical, neurobiological, and linguistic data of subgroups.
Subgroup 1
Patients

Subgroup 2
Patients

N
Demographics
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20

Age (years)

21.37 (3.72)

26.15
(5.31)

Female/Male

10/36

2/18

Education Scale
(1/2/3/4)

9/14/16/7

6/4/4/6

25.76 (7.02)

23.85
(5.91)
11.50
(3.64)

Clinical
PANSS-8 (Total)
PANSS-8 Positive

11.67 (3.46)

Patient Subgroup
Comparison

Pearson’s Chisquared test or
Welch T-tests
t (27.433) = 3.6527, p-value =
0.001081 *
X-squared (1) =
0.62274, p-value =
0.43
X-squared (3) =
3.7761, p-value =
0.2867
Welch T-tests
t (42.677) = 1.1376,
p-value = 0.2616
t (34.519) =
0.18146, p-value =
0.8571

Subgroup 1
Healthy
Controls
33

21.15 (3.08)

12/21

5/3/14/10

-
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PANSS-8 Negative

7.48 (4.46)

5.80 (4.15)

PANSS-8 General

5.22 (2.41)

5.10 (2.63)

DUP (weeks)
(median [IQR])

13 [4, 26]

8.5 [5.75,
16.5]

DDD lifetime
exposure
(median [IQR])
Functional
SOFAS

0 [0, 2.54]

1.25 [0,
3.9]

40.98
(13.19)

40.90
(10.67)

NEET status:
Yes/No

19/19

5/10

Glutamate (mM)

6.57 (1.03)

7.28 (1.30)

Mean cortical
thickness (mm)

2.50 (0.068)

2.32
(0.057)

1.28 (1.28)

1.93 (1.64)

TLI
Impoverishment

0.48 (0.61)

0.79 (0.92)

TLI
Disorganization

0.82 (1.14)

1.14 (1.37)

Average total
number of words

119.47
(35.45)

118.43
(47.46)

MLS

14.58 (4.01)

13.91
(5.89)

Neurobiological

Language
Variables
TLI (Total)

t (38.757) = 1.4755,
p-value = 0.1481
t (33.503) =
0.17063, p-value =
0.8655
t (23.362) = 0.53167, p-value =
0.6027
t (20.156) = 1.6477, p-value =
0.1149
Welch T-tests
t (44.354) =
0.025424, p-value =
0.9798
X-squared (1) =
0.62686, p-value =
0.4285
ANOVA with age
as a covariate
F(1)=5.10, p =
0.028 *
Age effect: p = 0.13
F(1)=126.225, p <
0.000 ***
Age effect: p = 0.12
Welch T-tests

-

t (29.517) = 1.5629, p-value =
0.1287
t (26.725) = 1.3843, p-value =
0.1777
t (30.974) = 0.92366, p-value =
0.3628
t (24.954) =
0.084721, p-value =
0.9332
t (23.59) = 0.4227,
p-value = 0.6763

0.28 (0.40)

-

-

-

-

6.50 (1.40)

2.49 (0.061)

0.13 (0.23)

0.16 (0.26)

141.53
(31.15)
14.03 (2.67)
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MLT

12.79 (3.09)

10.75
(2.20)

t (43.928) = 2.9509, 12.45 (2.13)
p-value = 0.005066
**
MLC
7.90 (1.25)
7.30 (0.96) t (40.658) = 2.0284, 8.24 (1.21)
p-value = 0.04911 *
Repeated contents 0.240
0.204
t (28.741) = 2.6991, 0.249 (0.034)
lemmas
(0.044)
(0.047)
p-value = 0.01152 *
ANOVA with age
as a covariate
TLI (Total)
F(1)=2.96, p = 0.090
Age effect: p = 0.39
TLI
F(1)=2.61, p = 0.11
Impoverishment
Age effect: p = 0.29
TLI
F(1)=1.00, p = 0.32
Disorganization
Age effect: p = 0.15
Average total
F(1)=0.009, p = 0.92
number of words
Age effect: p = 0.126
MLS
F(1)=0.25, p = 0.62
Age effect: p = 0.25
MLT
F(1)=6.46, p = 0.014 *
Age effect: p = 0.57
MLC
F(1)=3.30, p = 0.074
Age effect: p = 0.126
Repeated contents
F(1)=7.56, p = 0.0081 **
lemmas
Age effect: p = 0.515
Note: Values are reported as “Mean (SD)” unless specified otherwise. IQR: Interquartile
range. FEP: first episode psychosis; HC: healthy controls. PANSS: Positive and Negative
Symptoms Scale; DUP: duration of untreated psychosis; DDD: Defined Daily Dose;
SOFAS: Social and Occupational Functioning Assessment Scale; NEET: not in
employment, education and training; TLI: Thought and Language Index; MLS: mean
length of sentences, MLT: mean length of T-units, MLC: mean length of clauses.
* p values < 0.05
** p values < 0.01
*** p values < 0.001
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(A)

(B)

(C)

(D)

(E)
Figure 9 Raincloud plots depicting the comparisons of distributions between the two
patient subgroups.
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Figure 10 Cortical thickness map of differences between patients from Subgroup 1
and Subgroup 2 generated by FreeSurfer (regressing out age effect with a general
linear model, uncorrected). Left hemisphere and right hemisphere in lateral and
medial view respectively.

Figure 11 Cortical thickness map of differences between patients from Subgroup 1
and Subgroup 2 generated by FreeSurfer.
Note: Regressing out age effect with a general linear model, multiple comparison
corrections using Monte Carlo simulations of 1000 permutations with 1000
permutations with a cluster-wise threshold of 0.05). Left hemisphere and right
hemisphere in lateral and medial view respectively. The scale indicates log10 of p-
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values. Red and yellow represent higher cortical thickness in patients from
Subgroup 1.

Table 7 Cortical regions with their area size (mm2) showed significant differences
after Monte Carlo simulation correction between patients from the two subgroups,
in the left and right hemispheres respectively.
Left Hemisphere

Rostral middle frontal

1)
2)
3)
4)

Precentral

5) 389.09

Precuneus
Rostral anterior
cingulate
Postcentral
Lateral occipital

6) 289.00
7) 234.62

Inferior temporal
Lateral orbitofrontal

Lingual

1082.27
579.75
530.65
462.95

Right Hemisphere

1)
2)
3)
4)

560.93
260.59
420.84
247.97

5)
6)
7)
8)

437.17
333.73
266.67
258.06

8) 182.27
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Figure 12 Cortical regions that are correlated with dACC glutamate levels
(uncorrected) generated by FreeSurfer.
Note: Left and right hemispheres in lateral and medial view respectively. Blue/cyan
colours indicate negative correlations while red/yellow colours indicate positive
correlations.

3.3.2 Cluster Solution Consistency
The variations of the same clustering procedure are summarized Table 8. Overall, the
two-cluster solution was consistently the most favoured. Out of the 66 patients, 37
patients (56%) were consistently classified in the ‘cortically healthy’ subgroup while 14
patients (21%) were consistently classified in the ‘cortically impoverished’ subgroup,
adding up to 77% of patients classified concurrently in all scenarios.
Table 8. Sensitivity analyses to examine the effects of different methods on findings.
Variations

1
Patients only

(1) Types of
participants

Patients and
healthy controls
together

2
(original)

3

4

5
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(2) Clustering
Methods
(3) Parcellation
atlas

Hierarchical
clustering
K-means clustering
Destrieux
Schaefer

Dataset dimension
Number of validity indices that
suggested a 2-cluster solution
Number of patients classified to be
in the ‘cortical impoverished’
subgroup
% Misclassified, referencing to the
original analysis

66 x
148

102 x 148

102 x
200

102 x
148

102 x
200

9/16

9/16

11/16

9/16

11/16

27

20

19

27

27

10.6%

-

16.7%

13.6%

13.6%
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3.4

Discussion

3.4.1 ‘Cortical Impoverishment’ Subgroup
In the current study, we identified a subgroup of 30% of patients with first-episode
schizophrenia who are distinguishable on the basis of their MRI-derived cortical
thickness profiles – displaying a generalized reduction in thickness ( referred to as
“Subgroup 2”) compared to the other group (70%) who have an unimpaired thickness
profile similar to most healthy control subjects (referred to as “Subgroup 1”). Subgroup 2
is older in age at the time of the first presentation, has higher MRS-derived glutamate
levels in the dorsal ACC and showed a pattern of linguistic impoverishment characterized
by reduced fluency, syntactic simplicity, and repetitiveness. Taken together, these
observations indicate a distinct subtype of schizophrenia that shows a pattern of cortical
impoverishment along with linguistic impoverishment in the presence of higher
prefrontal (dACC) glutamate levels at first presentation.
The emergence of a cortical impoverishment group showing a distributed reduction in
cortical thickness compared to the other subgroup of patients and healthy controls is now
a well-established feature of cluster analytical studies in schizophrenia. In a prior work
where we studied two independent groups of patients with established schizophrenia as
well as a part of the sample reported here, we observed a reliably identifiable subgroup of
patients with cortical impoverishment (Liang, Heinrichs, et al., 2022), who did not differ
from other patients in the cognitive or clinical severity. Similar findings also reported a
‘cortical impoverishment subgroup’ at various illness stages (Chand et al., 2020a; Dwyer
et al., 2018a; Pan et al., 2020b; Sugihara et al., 2017b), supporting the stability of this
subtype.

3.4.2 Cortical Thinning and Glutamate Excess
While the mechanistic processes underlying this structural deviation are still circumspect,
the finding that the impoverished cortical thickness profile is associated with higher
glutamate levels in dACC provided robust evidence for the hypothesis that glutamateinduced toxicity relates to structural compromise in schizophrenia (Kritis et al., 2015;
Plitman et al., 2014). The relationship between structural impoverishment and glutamate
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dysregulations is supported by findings reporting that they appear to share similar risk
gene variants (Schultz et al., 2011), and are both associated with treatment resistance
(Egerton et al., 2018; J. Li et al., 2020; Shah et al., 2020; Zugman et al., 2013), negative
symptom severity (Reid et al., 2019; Walton et al., 2018; Wijtenburg et al., 2021) and
cognitive impairment (Godlewska et al., 2021; Hartberg et al., 2011; Wijtenburg et al.,
2021). According to the NMDA hypofunction or glutamatergic dysregulation models of
schizophrenia, higher glutamate transmission may relate to excitation-inhibition
imbalance (Limongi et al., 2020) and if unchecked, may result in synaptic and neuronal
loss (Wang & Qin, 2010). These cellular mechanisms have been hypothesized to underlie
structural deficits in schizophrenia (Plitman et al., 2014). Multilevel genetic and
physiological studies are needed to further pursue this observation. We now provide an
important lead in this pursuit by identifying language dysfunction in this subgroup of
schizophrenia.
However, one caveat to our observation is that we measured glutamate levels only from
the dACC, while cortical thickness reduction is more generalized. Prior results showing a
regional correspondence of glutamate levels and structure (Plitman et al., 2016; Shah et
al., 2020) indicate that this relationship is likely to be generalized across the brain.
Further, other groups have focused on glutamatergic excitotoxicity in the hippocampal
circuits (Lieberman et al., 2018). Taken together, our observations indicate that
glutamatergic dysregulation in one brain region (dorsal ACC in our case) may influence
the structure of other connected brain regions, either via distributed networks or through a
generalised glutamatergic dysfunction. This hypothesis can be tested using multi-voxel
MRS data (for example, see Kumar et al., 2020).

3.4.3 Cortical Thinning and Language Deficits
3.4.3.1

Syntactic Simplicity in ‘Cortical Impoverishment’ Subgroup

Through a parts-of-speech (POS) tagging approach in NLP, we studied “poverty of
content” at 3 components of grammatical structures: mean length of sentences, clauses
and T-units. All are large syntactic complexity indices used as a proxy of cognitive
parameters because producing a T-unit is a more complex process than producing
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coordinated clauses (Szmrecsanyi, 20040101). T-units serve as an informative index to
distinguish the amount of independent clausal coordination in the expressed idea.
Moreover, T-units provided the rule-based identification process considering the
selecting word for subordination (e.g., using ‘because’) or coordination (e.g., using
‘and ’) (Beaman, 1984). Therefore, a reduction in coordinated T-units demonstrates
notable syntactic simplicity in our Subgroup 2. These results are congruent with Bilgrami
and colleagues’ works (Bilgrami et al., 2022) who also reported lower POS syntactic
complexity in those patients who had negative symptoms. The authors found that reduced
sentence length and decreased use of words that introduce dependent clauses (e.g., using
complementizer or determiner pronouns such as “that” and “which”) are associated with
negative thought disorder (Bilgrami et al., 2022). Additionally, our observations raise the
question of whether patients with higher developmental disruption form the subgroup
with cortical and linguistic impoverishment since syntactic complexity is a phenomenon
that develops during childhood (Frizelle et al., 2018; Givon, n.d.) and reaches a plateau
around the age of 20 (Nippold et al., 2014). If developmental disturbances during
childhood and adolescence lie in the pathogenesis of schizophrenia and can be detected
using NLP tools (via progressive aberrations in syntactic complexity; see Silva et al.
(Silva et al., 2022)), this may provide a promising avenue for early identification.

3.4.3.2

Impaired Cohesion in ‘Cortical Impoverishment’ Subgroup

We observed a reduction of repeated content lemma (e.g., nouns, verbs, adjectives) in
our Subgroup 2. This index traditionally characterizes the systematic relationship –
explicit or implicit – between lexical items, i.e., cohesive cues, placed at the text surface
(Sanders & Maat, 1976). For example, if two adjacent ideas (sentence-to-sentence,
clause-to-clause) comprise the same noun (e.g., woman), the lexical repetition will
explicitly help connect both ideas. However, if the first clause contains the word “bridge”
and the second contains the word “iron”, the connection weakens even though it is
logical. Therefore, in this work, we quantify cohesion (Graesser et al., 2004; Halliday &
Hasan, 1976) through a lexical approach applied to how speech has been produced,
without any assumption about how it is understood by listeners or readers (i.e., lexical
cohesion as distinct from semantic coherence) (Just et al., 2020).
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The linguistic phenomenon of reduced content word-lemmas relating to cortical thinning
can be understood in several ways (Crossley et al., 2016). Firstly, reduced repetition of
content-lemmas directly negatively influences the givenness of the generated speech.
Givenness refers to the distribution of the given/known information or ideas as opposed
to the new/unknown information. A ‘cortically impoverished’ patient may build ideas as
small clauses with little relationship between them. Secondly, a decline in the use of
repeated content lemma makes it difficult to recover the meaningful information from the
preceding passage, generating a sense of empty speech (i.e., poverty of content) with
reduced informative value to the listener.

3.4.4 Strengths
Our study has several strengths: We were able to overcome the difficulty of collecting
speech data in an acute, untreated state of psychosis, and determine their diagnosis of
first-episode schizophrenia. Furthermore, we ensured transcribers, as well as speech
analysts, were blind to diagnosis. We employed ultra-high field strength MRS whereby
the glutamate quantification from MS-spectra had a high specificity. Third, we used
multiple clustering procedures and derived a two-cluster solution based on a majoritybased consensus, adding to the stability of the observed subtype. Finally, in clinical
settings, linguistic dysfunction in schizophrenia traditionally relies on a standardized
rating scale (PANSS and TLI) to define speech impairment as one sign of formal thought
disorder (FTD) (Elvevåg et al., 2007; Iter et al., 2018). Instead, we used automated
quantitative processes to parse the subtler aspects of language dysfunction, and our
results speak to the ability of using NLP tools to detect minor language impairments that
cannot be detected with subjective clinical rating scales (Corcoran & Cecchi, 2020;
Hitczenko et al., 2021).

3.4.5 Limitations
Nevertheless, several limitations need consideration. We had a limited number of female
participants which limits generalizability; we did not see a statistical effect of sex
between the groups, but our small numbers preclude a stratified analysis. Second,
thickness-based clustering resulted in age differences between the subgroups; however,

58

we included age as a covariate in downstream analyses for glutamate and regional
thickness to ensure this confound did not affect the inferences we make. Nevertheless, the
non-linear influence of age on these variables cannot be ruled out. Third, we did not
assess IQ formally. In our recent study where we examined the influence of cognition on
thickness-based clustering in greater detail, the effect of individual differences in
cognitive performance in the thickness profile was minimal among patients (Liang,
Heinrichs, et al., 2022). Thus, while we can be confident that the reported thickness
reduction and language dysfunction in a subgroup is not due to low extreme distributions
of IQ as a result, we cannot exclude that an undetermined proportion of variance in these
variables could be explained by cognitive differences. Finally, our speech samples were
restricted to one language (English) and were based on a single discursive discourse
(picture description) and single modality (oral soliloquies-monologue) elicited in the
context of a research interview. The effect of contextual differences, language as well as
types and duration of elicitation task on our linguistic observations needs further
examination.
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Chapter 4

Conclusions

Neuroanatomical heterogeneity exists in schizophrenia, but such variations are not
restricted to the illness per se because we can also see it in healthy populations.
Leveraging the variances of cortical thickness data of patients and healthy controls, we
identified two subgroups based on cortical thickness profiles across the whole brain.
Despite displaying similar symptom severity and social functioning, the two patient
subgroups have distinct neurobiological underpinnings, and may represent different
pathophysiological pathways of developing schizophrenia. The cortical thickness-based
data-driven two-cluster solution presented here emerges as an invariant feature across
illness stages, acute symptom severity, functional status, and treatment exposure. The
two-cluster typology remains robust when reproducing it across different patient samples
and varying the choices of brain parcellation atlases or clustering algorithms.
A ‘cortical impoverished’ subgroup was consistently seen across the 3 samples
irrespective of illness duration, stage, or state, and the strength of the scanners used. We
can link the putative excitotoxicity (glutamate excess) to reduced grey matter thickness
(cortical impoverishment) and the objectively computed negative phenomenology of
language (or linguistic impoverishment) in first-episode schizophrenia. Connecting the
cellular/synaptic processes (glutamate) with objectively quantified language behaviours
through macroscopic brain changes (thickness) may facilitate more consistent brainbehaviours mapping in schizophrenia. While cortical thinning is neither necessary nor
sufficient for clinical expression, a specific mechanistic pathway operating via glutamate
excess and resulting in language production impairment in the early stage of
schizophrenia as well as a higher residual symptom burden in chronic schizophrenia may
present with cortical impoverishment in schizophrenia.

4.1

Future Directions

The current study validated and characterized a ‘cortical impoverishment’ subgroup of
schizophrenia in terms of symptom, cognition, functional outcome, language and
neurometabolite. Further investigations into the genetic makeup and other biological
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features (e.g., functional brain activities, inflammatory markers), as well as the
longitudinal outcome and stability of this subgroup, could be of interest for future studies.
The ultimate goal of finding meaningful patient subtypes is to assist biomarkers-guided
clinical decisions and improve treatment outcomes for patients. To find the most
clinically relevant cluster solutions, future studies that pursue the efforts in uncovering
patients subtypes in schizophrenia can consider the followings:
1) Extensive external validation to facilitate brain-behaviours mapping across
various patient samples. To consider a subgroup generated from cluster analytic
algorithms to be a meaningful subtype, it is important to externally validate the
clusters extensively across various features including genetics, symptoms,
outcome, course, neurobiology, and cognition (Seaton et al., 2001; Tamminga et
al., 2017). Patient subtypes only become clinically meaningful when they are
validated, reproducible and carefully characterized.
2) Investigation of the longitudinal outcome and stability of the subgroups. The
diagnostic construct of schizophrenia lacks corresponding neurobiological
features observable in all patients. Instead, multiple abnormalities have been
reported that nest variably within portions of the patient distribution. In this
context, one of the key questions in the pursuit of subtypes of this illness is the
longitudinal stability of any typology identified.
3) Consistency across various cluster solutions. In the investigation of the
heterogeneity of schizophrenia, the cluster solutions were highly dependent on the
choice of variables and clustering algorithms (Marquand et al., 2016). A
challenging but necessary step before biomarkers-guided clinical decisions is to
compare and evaluate the different subtyping solutions reported in the cluster
analytic studies. This effort has been lacking in the literature (Schnack, 2019).
Evaluations of different subtyping solutions will be informative when we need to
decide which one is the most clinically relevant. The most ideal theoretical
framework(s) would be to find consistency between these subtyping solutions, as
well as use it to predict the course and outcome of schizophrenia [see a model for
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heterogeneity proposed by Seaton et al. (2001)]. The redundancy, agreement, and
lack thereof among various data-driven subtyping solutions require further
examination of multiple biological and symptomatic correlates before clinically
feasible recommendations can be made.
4) Parsing heterogeneity in multimodal cross-domain features. Most subtyping
studies so far account for heterogeneity in only one of these characteristics –
symptom, cognition, neurobiology or genetics. Very few studies have attempted
to parse heterogeneity across different feature spaces, for example, by combining
biological and clinical data (Schnack, 2019).
Luxburg and colleagues raised the question of whether clustering is an art or science,
highlighting the difficulty with unsupervised clustering as it throws a huge number of
possibilities regarding how it is administered and what its implications are (Luxburg et
al., 2012). Cluster algorithms will always provide us with a cluster solution, and whether
it is deemed useful or useless depends on how and when it can be used for inference. It is
sensible to conclude the work presented here with the same sentiment: cortical
impoverishment cluster, if mapped successfully onto treatment selection, adjustment, or
tailoring, will be immensely helpful in developing personalized patient care and
advancing precision psychiatry. With such clinically meaningful utility, morphological
clustering may advance us beyond the impasse in the treatment of schizophrenia.
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Appendices
Appendix A. Language Metrics
Measures

Dimensions

Detailed Descriptions

Poverty of speech

Speech productions lack details and
elaboration

Weakening of goal

Lack of ideas and meaningful information

Preservation of ideas

Repetitive contents, even if given different
stimuli

Looseness

Lack of logical flow or connection of ideas

Thought and
Language Index
Impoverishment

Disorganization
Peculiar use of words Invented or rarely used words

Syntactic
Complexity
(Production)

Cohesion

Peculiar sentences

Unusual sentence structures that impede
speech comprehension

Peculiar logic

Reaching conclusions without enough
evidence

Distractibility

Distracted by external stimulus

Mean length of
sentences (MLS)

Average number of words per sentence.

Mean length of Tunits (MLT)

Average number of words per T-unit. Tunit is defined as the main clause with its
attached subordinate clause(s).

Mean length of
clauses (MLC)

Average number of words per clause.

Repeated contents
lemmas

Average number of content words that are
repeated at least once divided by the total
number of words in the text
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Appendix B. Patient Speech Data Examples
Example output of syntactic complexity. Traditional indices from Tool for the automatic analysis
of syntactic complexity and sophistication (TAASSC)
ID

Pictur
Transcribe speech
e

FEPxx
2
x

MeanMLS

Uh there is a black and white sun seen in
all the building all the big painted
building It is wood there is three
windows there is a girl that is looking
down from the balcony there is water
down on the water there is another an
7.417
abandoned building there is a guy in a
canoe there is lots of workers maybe
gathering up some fish and that is it that
is all I can get uh it is black and white
pencil sketched

MeanMLT MeanMLC

7.639

6.078

Example output of Textual cohesion based upon the givenness index. Tool for the Automatic
Analysis of Cohesion (TAACO) 2.0.4

ID

Pictur
Transcribe speech
e

FEPxx
1
x

Repeated
contents
lemmas
(Givenness)

Um he is looking at an enemy who is
done wrong to him and she is trying to
console him they are both of uh decent
socioeconomic status they have nice
clothing nicely cropped hair and uh he is
probably he is probably under the
influence of alcohol and uh I think he
0.160
like there is something going on
underneath the surface for him that she
does not know about but she is still there
trying to, trying to face things for him
there is a woman in the background so
that probably suggests that um I do not
know

Repeated_content_and_
pronoun_lemmas
(Givenness)

0.320

Note. MLS: mean length of sentences; MLT: mean length of T-units; MLC: mean length
of clauses. Givenness: It is an average number of content words that are repeated at least
once divided by the total number of words in the text.
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Appendix C. Tissue volume fractions in the voxel placed in dorsal anterior cingulate
cortex.
Healthy controls
(N = 36)

Total
(N = 102)

Grey matter

First-episode
psychosis
(N = 66)
0.5590 ± 0.0620

0.5911 ± 0.0502

0.5701 ± 0.0599

White matter

0.2041 ± 0.0706

0.1961 ± 0.0379

0.2014 ± 0.0612

Cerebrospinal
0.2367 ± 0.0740
0.2128 ± 0.0591
0.2285 ± 0.0698
fluid
Note: Values are reported as mean ± standard deviation of tissue proportion in the voxel.

Appendix D. Description of single voxel 1H-MRS of MRS hardware, data
acquisition, analysis, and quality assessment details.
1. Hardware
a. Field strength [T]
b. Manufacturer
c. Model (software version if available)
d. RF coils: nuclei (transmit/receive), number
of channels, type, body part
e. Additional hardware
2. Acquisition
a. Pulse sequence
b. Volume of Interest (VOI) locations
c. Nominal VOI size [cm3, mm3]
d. Repetition Time (TR), Echo Time (TE)
[ms,s]
e. Total number of excitations or acquisitions
per spectrum

7-Tesla
Siemens
VB17
32 channel head coil (8-channel Tx,
32-channel Rx)
N/A
semi-LASER
Bilateral dorsal anterior cingulate
cortex
2 x 2 x 2 cm3
TR = 7500ms, TE = 100ms
32 averages, 1 measurement

f. Additional sequence parameters (spectral
width in Hz, number of spectral points,
frequency offsets)

2048 points

g. Water Suppression Method
h. Shimming Method, reference peak, and
thresholds for “acceptance of shim” chosen
i. Triggering or motion correction method

VAPOR
FASTESTMAP

3. Data analysis methods and outputs
a. Analysis software

N/A
MATLAB, fitMAN, Barstool
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b. Processing steps deviating from quoted
reference or product
c. Output measure
(e.g. absolute concentration, institutional units,
ratio)
d. Quantification references and assumptions,
fitting model assumptions

N/A
Absolute concentration

Each spectrum was phase and
frequency corrected to the first
spectral acquisition before being
averaged into a single spectrum for
further post-processing. 17 brain
metabolites (described in Methods)
were included our fitting template
and quantification analysis.

4. Data Quality
a. Reported variables
SNR
(SNR, Linewidth (with reference peaks))
b. Data exclusion criteria
No subjects excluded
c. Quality measures of postprocessing Model
CRLB
fitting (e.g. CRLB, goodness of fit, SD of
residual)
d. Sample Spectrum
See Supplementary Figure 4
Note: This table was based on a MRS reporting standardized template provided by Lin et
al. (2021)
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Appendix E. Two different cortical parcellation maps
Lateral View
Schaefer Parcellation
ROI = 200

Destrieux Parcellation
ROI = 148

Medial View
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Appendix F. Bash Scripts and R Codes
Bash script to
reconstruct brain
surfaces and calculate
vertex-wise thickness
values in FreeSurfer

#!/usr/bin/env bash
export SUBJECTS_DIR=/media/sf_subjects/recon

Bash script to extract
thickness values
based on Destrieux
parcellation
(Destrieux et al.,
2010b)

# define subjects data directory path
export SUBJECTS_DIR=/home/charlotte/Desktop/recon

for subj in `ls ./nifti`
do
recon-all -s $subj -i ./nifti/$subj/*.nii -all -qcache
done

# output stats from recon-all
aparcstats2table --hemi lh \
--meas thickness \
--parc aparc.a2009s \
--tablefile 211108_lh_thicknes_destrieux.txt \
--subjects
aparcstats2table --hemi rh \
--meas thickness \
--parc aparc.a2009s \
--tablefile 211108_rh_thicknes_destrieux.txt \
--subjects

Bash script to output
cortical thickness map
of differences
between two
subgroups (regressing
out age effect with a
general linear model,
multiple comparison
corrections using
Monte Carlo
simulations of 1000
permutations with a
cluster-wise threshold
of 0.05)

export SUBJECTS_DIR=/home/charlotte/Desktop/recon
cat group_diff.fsgd | sed 's/\r/\n/g' > new.group_diff.fsgd
# Resampling subjects data into a common space; spatial
soothing
mris_preproc --fsgd new.group_diff.fsgd --target fsaverage -hemi lh --meas thickness --out lh_group_diff.mgh
mris_preproc --fsgd new.group_diff.fsgd --target fsaverage -hemi rh --meas thickness --out rh_group_diff.mgh
# GLM model fit
mri_glmfit --y lh_group_diff.mgh --fsgd new.group_diff.fsgd --C
group_diff.mtx --glmdir group.age_10sm.lh --fwhm 10 --surface
fsaverage lh --eres-save
mri_glmfit --y rh_group_diff.mgh --fsgd new.group_diff.fsgd --C
group_diff.mtx --glmdir group.age_10sm.rh --fwhm 10 --surface
fsaverage rh --eres-save
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# Multiple testing correction
mri_glmfit-sim --glmdir group.age_10sm.lh --2spaces --cwp 0.05
--perm 1000 3 abs
mri_glmfit-sim --glmdir group.age_10sm.rh --2spaces --cwp 0.05
--perm 1000 3 abs
R codes to run
clustering procedure
and other statistical
analyses

#Import dataset generated by FreeSurfer---TOPSY <- read_excel("E:/subjects/Bash
Scripts/TOPSY_destrieux_thickness_211108_66FEP36HC.xlsx")
TOPSY_thickness <- as.data.frame(TOPSY[c(37:184)])
rownames(TOPSY_thickness) <- TOPSY$ID
# Use original thickness values for clustering ---# Hierarchical Cluster Analysis
TOPSY_dist <- dist(TOPSY_thickness, method = "euclidean")
TOPSY_hc_ward <- hclust(TOPSY_dist, method = "ward.D2")
TOPSY_cluster_solution <- matrix(rep(0,
len=length(selected)),nrow = length(selected))
for (i in 1:length(selected)){
TOPSY_cluster_solution[i,] <unname(NbClust::NbClust(TOPSY_thickness, min.nc=1,
max.nc=8, method="ward.D2", index=selected[i])$Best.nc)[1]
}
barplot(table(TOPSY_cluster_solution), main = "Barplot of
Proposed Cluster Solutions",xlab="Number of Clusters")
plot(TOPSY_hc_ward)
rect.hclust(TOPSY_hc_ward, k = 2)
TOPSY_2clusters <- cutree(TOPSY_hc_ward, k=2)
# Subgroups Statistics
TOPSY$cluster = TOPSY_2clusters
# Explore two-cluster solution
TOPSY_TypeCluster <table(data.frame(TOPSY$Type,TOPSY$cluster))
barplot(TOPSY_TypeCluster,xlab="cluster assignment",
ylab="patient or control",
main="Patient & control in each
cluster",legend=rownames(TOPSY_TypeCluster))
chisq.test(TOPSY_TypeCluster)
write.csv(TOPSY_FEP,"E:/TOPSY/TOPSY_FEP_FULL.csv")
# Use original thickness and clustering with FEP only ---# Hierarchical Cluster Analysis
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TOPSY_FEP_thickness <- as.data.frame(TOPSY_FEP[c(37:184)])
TOPSY_dist <- dist(TOPSY_FEP_thickness, method = "euclidean")
TOPSY_hc_ward <- hclust(TOPSY_dist, method = "ward.D2")
TOPSY_cluster_solution <- matrix(rep(0,
len=length(selected)),nrow = length(selected))
for (i in 1:length(selected)){
TOPSY_cluster_solution[i,] <unname(NbClust::NbClust(TOPSY_thickness, min.nc=1,
max.nc=8, method="ward.D2", index=selected[i])$Best.nc)[1]
}
barplot(table(TOPSY_cluster_solution), main = "Barplot of
Proposed Cluster Solutions",xlab="Number of Clusters")
plot(TOPSY_hc_ward)
rect.hclust(TOPSY_hc_ward, k = 2)
TOPSY_2clusters <- cutree(TOPSY_hc_ward, k=2)
# Subgroups Statistics
TOPSY_FEP$cluster_FEP = TOPSY_2clusters
# Check cluster consistency
cluster_consistency_table <table(data.frame(TOPSY_FEP$cluster,TOPSY_FEP$cluster_FEP))
barplot(cluster_consistency_table, xlab="x", ylab="y",
main="Cluster Consistency")
R codes to run
correlation matrices
and draw raincloud
plots

# Correlations between symptom and language scores ---TOPSY_Language2$MeanThickness <- TOPSY$meanThickness
CorMatrix <- TOPSY_Language2[,c(3,7:8,18,24,30,40:43,60,62)]
#variables of all participants
corrplot.mixed(cor(CorMatrix, method = "pearson", use =
"pairwise.complete.obs"))
corrplot(cor(CorMatrix, method = "pearson", use =
"pairwise.complete.obs"),addCoef.col = 'black',type =
'lower',diag = FALSE)
CorMatrix_FEP <- subset(TOPSY_Language2, Type
=="FEP")[,c(3,7:8,18,24,30,40:43,60,62)] #variables of FEP only
colnames(CorMatrix_FEP) = c("Age", "PANSS Positive", "PANSS
Negative","SOFAS","Glutamate","TLI","Number of Words",
"MLS","MLT","MLC","Repeated content
lemmas", "Mean Cortical Thickness")
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corrplot(cor(CorMatrix_FEP, method = "pearson", use =
"pairwise.complete.obs"),addCoef.col = 'black',type =
'lower',diag = FALSE,tl.srt = 30)
CorMatrix_FEP1 <- subset(subset(TOPSY_Language2, Type
=="FEP"),cluster==1)[c(3,7:8,18,24,30,40:43,60,62)] #variables
of FEP1 only
colnames(CorMatrix_FEP1) = c("Age", "PANSS Positive", "PANSS
Negative","SOFAS","Glutamate","TLI","Number of Words",
"MLS","MLT","MLC","Repeated content
lemmas", "Mean Cortical Thickness")
corrplot(cor(CorMatrix_FEP1, method = "pearson", use =
"pairwise.complete.obs"),addCoef.col = 'black',type =
'lower',diag = FALSE,tl.srt = 30)
CorMatrix_FEP2 <- subset(subset(TOPSY_Language2, Type
=="FEP"),cluster==2)[c(3,7:8,18,24,30,40:43,60,62)] #variables
of FEP2 only
colnames(CorMatrix_FEP2) = c("Age", "PANSS Positive", "PANSS
Negative","SOFAS","Glutamate","TLI","Number of Words",
"MLS","MLT","MLC","Repeated content
lemmas", "Mean Cortical Thickness")
corrplot(cor(CorMatrix_FEP2, method = "pearson", use =
"pairwise.complete.obs"),addCoef.col = 'black',type =
'lower',diag = FALSE,tl.srt = 30)
CorMatrix_HC <- subset(TOPSY_Language2, Type
=="HC")[c(3,24,30,40:43,60,62)] #variables of HC only
colnames(CorMatrix_HC) = c("Age", "Glutamate","TLI","Number
of Words",
"MLS","MLT","MLC","Repeated content
lemmas", "Mean Cortical Thickness")
corrplot(cor(CorMatrix_HC, method = "pearson", use =
"pairwise.complete.obs"),addCoef.col = 'black',type =
'lower',diag = FALSE,tl.srt = 30)
# Raincloud plots for variables ---remotes::install_github('jorvlan/raincloudplots')
library(raincloudplots)
#Define plotting raincloud plot function
Plot_raincloud <- function(variable){
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variable_rain <- data_1x1(array_1 =
subset(subset(TOPSY_Language2,
cluster==1),Type=="FEP")[[variable]],
array_2 = subset(subset(TOPSY_Language2,
cluster==2),Type=="FEP")[[variable]],
jit_distance = 0.2,
jit_seed = 321)
variable_raincloud <- raincloud_1x1(data=variable_rain,
#colors = (c('dodgerblue','darkorange')),
#fills = (c('dodgerblue','darkorange')),
size = 1.5,
alpha = .6,
ort = 'h') +
scale_x_continuous(breaks=c(1,2), labels=c("Subgroup 1",
"Subgroup 2"), limits=c(0, 3)) +
xlab("Patients") +
theme_classic()
return(variable_raincloud)
}
#Glutamate raincloud
Glu_raincloud <- Plot_raincloud(variable = "Rest_Glu")
Glu_raincloud + ylab("Glutamate Concentrations in dACC")
#Thickness raincloud
Thickness_raincloud <- Plot_raincloud(variable =
"MeanThickness")
Thickness_raincloud + ylab("Mean Cortical Thickness")
#Age raincloud
Age_raincloud <- Plot_raincloud(variable = "Age")
Age_raincloud + ylab("Age")
#MLT raincloud
MLT_raincloud <- Plot_raincloud(variable = "Mean-MLT")
MLT_raincloud + ylab("Mean length of T-units")
#repeated contents lemmas raincloud
RCL_raincloud <- Plot_raincloud(variable =
"repeated_content_lemmas")
RCL_raincloud + ylab("Repeated contents lemmas")
#total words raincloud
words_raincloud <- Plot_raincloud(variable = "Mean-nwords")
words_raincloud + ylab("Total number of words per 1-minute
task")
#DUP&DDD distribution
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ggplot(TOPSY_Language2_patient, aes(x=DUP_Weeks, fill =
cluster)) + geom_density(alpha=.3) + xlim(0,120) +
xlab("Duration of untreated psychosis in weeks")
ggplot(TOPSY_Language2_patient, aes(x=DDD_LifeTime, colour
= cluster)) + geom_density() + xlim(0,25) + xlab("DDD lifetime
exposure")

Appendix G. Journal Copyright Policies

Note: This screenshot is obtained from the Frontiers webpage on their journal policies on
reusing text from published manuscript (https://www.frontiersin.org/guidelines/policiesand-publication-ethics).
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Note: This screenshot is obtained from the Elsevier (publisher for Schizophrenia
Research) webpage on their journal policies on reusing text from published manuscript
(https://www.elsevier.com/about/policies/copyright).
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